1
|
Hong C, Wang A, Xia J, Liang J, Zhu Y, Wang D, Zhan H, Feng C, Jiang X, Pan J, Wang J. Ginsenoside Rh2-Based Multifunctional Liposomes for Advanced Breast Cancer Therapy. Int J Nanomedicine 2024; 19:2879-2888. [PMID: 38525007 PMCID: PMC10961064 DOI: 10.2147/ijn.s437733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Accepted: 03/07/2024] [Indexed: 03/26/2024] Open
Abstract
Background Most solid tumors are not diagnosed and treated until the advanced stage, in which tumors have shaped mature self-protective power, leading to off-target drugs and nanomedicines. In the present studies, we established a more realistic large tumor model to test the antitumor activity of a multifunctional ginsenoside Rh2-based liposome system (Rh2-lipo) on advanced breast cancer. Methods Both cholesterol and PEG were substituted by Rh2 to prepare the Rh2-lipo using ethanol-water system and characterized. The effects of Rh2-lipo on cell uptake, penetration of the tumor spheroid, cytotoxicity assay was investigated with 4T1 breast cancer cells and L929 fibroblast cells. The 4T1 orthotopic-bearing large tumor model was established to study the targeting effect of Rh2-lipo and inhibitory effect of paclitaxel loaded Rh2-lipo (PTX-Rh2-lipo) on advanced breast tumors. Results Rh2-lipo exhibit many advantages that address the limitations of current liposome formulations against large tumors, such as enhanced uptake in TAFs and tumor cells, high targeting and penetration capacity, cytotoxicity against TAFs, normalization of the vessel network, and depletion of stromal collagen. In in vivo study, PTX-Rh2-lipo effectively inhibiting the growth of advanced breast tumors and outperformed most reported PTX formulations, including Lipusu® and Abraxane®. Conclusion Rh2-lipo have improved drug delivery efficiency and antitumor efficacy in advanced breast cancer, which offers a novel promising platform for advanced tumor therapy.
Collapse
Affiliation(s)
- Chao Hong
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, People’s Republic of China
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People’s Republic of China
| | - Anni Wang
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, People’s Republic of China
| | - Jiaxuan Xia
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, People’s Republic of China
| | - Jianming Liang
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, People’s Republic of China
- Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006, People’s Republic of China
| | - Ying Zhu
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, People’s Republic of China
| | - Dan Wang
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, People’s Republic of China
- Xiamen Ginposome Pharmaceutical Co., Ltd, Xiamen, 361026, People’s Republic of China
| | - Huaxing Zhan
- Xiamen Ginposome Pharmaceutical Co., Ltd, Xiamen, 361026, People’s Republic of China
| | - Chunbo Feng
- R&D Center, Shanghai Jahwa United Co., Ltd, Shanghai, 200082, People’s Republic of China
| | - Xinnan Jiang
- R&D Center, Shanghai Jahwa United Co., Ltd, Shanghai, 200082, People’s Republic of China
| | - Junjie Pan
- Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, 200040, People’s Republic of China
| | - Jianxin Wang
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, People’s Republic of China
- Institute of Integrated Chinese and Western Medicine, Fudan University, Shanghai, 200040, People’s Republic of China
| |
Collapse
|
2
|
Wu XF, Sun TT, Lin JL, Guo WL, Li XY, Hong C. [Pulmonary artery stenting in chronic thromboembolic pulmonary hypertension: a report of 2 cases]. Zhonghua Jie He He Hu Xi Za Zhi 2024; 47:228-232. [PMID: 38448172 DOI: 10.3760/cma.j.cn112147-20230921-00184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/08/2024]
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a pulmonary vascular disease characterized by an insidious onset, progressive deterioration, and poor prognosis. It is distinguished by the thrombotic organization within the pulmonary arteries, leading to vascular stenosis or occlusion. This results in a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, ultimately leading to right heart failure. In recent years, balloon pulmonary angioplasty (BPA) has emerged as an effective treatment option for patients ineligible for pulmonary endarterectomy (PEA). However, the use of stents in patients with suboptimal balloon dilation remains controversial. This article describes two cases of chronic thromboembolic pulmonary hypertension (CTEPH) in which balloon angioplasty yielded unsatisfactory results, subsequently leading to stent placement. Following stent implantation, there was improved blood flow, significant reduction in pulmonary arterial pressure, and notable alleviation of patient symptoms. One-year follow-up showed no recurrence of stenosis within the stent, suggesting potential guidance for the use of pulmonary artery stenting as a treatment modality for CTEPH. This report provided new insights into the therapeutic approach for CTEPH.
Collapse
Affiliation(s)
- X F Wu
- Guangzhou Institute of Respiratory Health (National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine), The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China
| | - T T Sun
- Guangzhou Institute of Respiratory Health (National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine), The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China
| | - J L Lin
- Department of Radiology and Interventianl, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China
| | - W L Guo
- Guangzhou Institute of Respiratory Health (National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine), The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China
| | - X Y Li
- Guangzhou Institute of Respiratory Health (National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine), The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China
| | - C Hong
- Guangzhou Institute of Respiratory Health (National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine), The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China
| |
Collapse
|
3
|
Hong C, Li L, Zou JY, You SY, Wang EL, Zhang L, Liu YW, Huang YL. On-Off Ratiometric Fluorescence Europium(III) Metal-Organic Framework for Quantitative Detection of the Inflammatory Marker Neopterin. Inorg Chem 2024; 63:4697-4706. [PMID: 38407040 DOI: 10.1021/acs.inorgchem.3c04357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2024]
Abstract
Benefiting from the unique photoluminescence behavior of the lanthanide(III) ions and organic ligands, a lanthanide(III) metal-organic framework (Ln-MOF) material can simultaneously demonstrate photoluminescence of lanthanide(III) cations and organic molecules and endow its superior applications of fluorescence sensing behaviors. Herein, we present a europium(III) MOF material {[Eu2(BPTA)·(CH3COO)2·3DMA]·0.5DMA·3H2O}n (1) (where H4BPTA is 3,3',5,5'-biphenyltetracarboxylic acid) for photoluminescence performance of quantitatively sensing the inflammatory marker neopterin (Neo). The obtained 1 comprises Eu2(COO)4 paddlewheel secondary building units, which could be bridged by BPTA4- ligands to extend a 2D framework. The fluorescence titration indicates 1 can achieve simultaneous fluorescence behavior of Eu3+ ions and Neo via on-off ratiometric effects and thus could be exploited as the ratiometric fluorescence sensor matrix. Such a fluorescence phenomenon of 1 as a ratiometric sensor for quantitative detection of Neo via an on-off ratiometric effect is never observed in MOF chemistry. Moreover, naked-eye visible color variations of the fluorescence for 1 could be observed from red to blue with increasing concentrations of Neo, confirmed by fluorescent test strips as well as portable fluorescent hydrogels. And 1 also shows a low detection limit of 15.11 nM. A synergetic contribution of the competitive absorption, fluorescence resonance energy-transfer, and photoinduced electron-transfer mechanisms between Neo and the framework of 1 realizes the on-off ratiometric fluorescence behavior for Neo detection, supported by the UV-vis spectral overlap experiment and DFT calculations.
Collapse
Affiliation(s)
- Chao Hong
- Institute of Applied Chemistry, Jiangxi Academy of Sciences, Nanchang 330096, PR China
- School of Materials Science and Engineering, Nanchang Hangkong University, Nanchang 330063, PR China
| | - Ling Li
- Institute of Applied Chemistry, Jiangxi Academy of Sciences, Nanchang 330096, PR China
| | - Ji-Yong Zou
- Institute of Applied Chemistry, Jiangxi Academy of Sciences, Nanchang 330096, PR China
| | - Sheng-Yong You
- Institute of Applied Chemistry, Jiangxi Academy of Sciences, Nanchang 330096, PR China
| | - Er Li Wang
- Institute of Applied Chemistry, Jiangxi Academy of Sciences, Nanchang 330096, PR China
- School of Environmental and Chemical Engineering, Nanchang Hangkong University, Nanchang 330063, PR China
| | - Li Zhang
- Institute of Applied Chemistry, Jiangxi Academy of Sciences, Nanchang 330096, PR China
| | - Yue-Wei Liu
- Institute of Applied Chemistry, Jiangxi Academy of Sciences, Nanchang 330096, PR China
| | - You-Lin Huang
- School of Materials Science and Engineering, Nanchang Hangkong University, Nanchang 330063, PR China
| |
Collapse
|
4
|
Jung T, Milenković I, Balci Y, Janoušek J, Kudláček T, Nagy Z, Baharuddin B, Bakonyi J, Broders K, Cacciola S, Chang TT, Chi N, Corcobado T, Cravador A, Đorđević B, Durán A, Ferreira M, Fu CH, Garcia L, Hieno A, Ho HH, Hong C, Junaid M, Kageyama K, Kuswinanti T, Maia C, Májek T, Masuya H, Magnano di San Lio G, Mendieta-Araica B, Nasri N, Oliveira L, Pane A, Pérez-Sierra A, Rosmana A, Sanfuentes von Stowasser E, Scanu B, Singh R, Stanivuković Z, Tarigan M, Thu P, Tomić Z, Tomšovský M, Uematsu S, Webber J, Zeng HC, Zheng FC, Brasier C, Horta Jung M. Worldwide forest surveys reveal forty-three new species in Phytophthora major Clade 2 with fundamental implications for the evolution and biogeography of the genus and global plant biosecurity. Stud Mycol 2024; 107:251-388. [PMID: 38600961 PMCID: PMC11003442 DOI: 10.3114/sim.2024.107.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Accepted: 01/15/2024] [Indexed: 04/12/2024] Open
Abstract
During 25 surveys of global Phytophthora diversity, conducted between 1998 and 2020, 43 new species were detected in natural ecosystems and, occasionally, in nurseries and outplantings in Europe, Southeast and East Asia and the Americas. Based on a multigene phylogeny of nine nuclear and four mitochondrial gene regions they were assigned to five of the six known subclades, 2a-c, e and f, of Phytophthora major Clade 2 and the new subclade 2g. The evolutionary history of the Clade appears to have involved the pre-Gondwanan divergence of three extant subclades, 2c, 2e and 2f, all having disjunct natural distributions on separate continents and comprising species with a soilborne and aquatic lifestyle and, in addition, a few partially aerial species in Clade 2c; and the post-Gondwanan evolution of subclades 2a and 2g in Southeast/East Asia and 2b in South America, respectively, from their common ancestor. Species in Clade 2g are soilborne whereas Clade 2b comprises both soil-inhabiting and aerial species. Clade 2a has evolved further towards an aerial lifestyle comprising only species which are predominantly or partially airborne. Based on high nuclear heterozygosity levels ca. 38 % of the taxa in Clades 2a and 2b could be some form of hybrid, and the hybridity may be favoured by an A1/A2 breeding system and an aerial life style. Circumstantial evidence suggests the now 93 described species and informally designated taxa in Clade 2 result from both allopatric non-adaptive and sympatric adaptive radiations. They represent most morphological and physiological characters, breeding systems, lifestyles and forms of host specialism found across the Phytophthora clades as a whole, demonstrating the strong biological cohesiveness of the genus. The finding of 43 previously unknown species from a single Phytophthora clade highlight a critical lack of information on the scale of the unknown pathogen threats to forests and natural ecosystems, underlining the risk of basing plant biosecurity protocols mainly on lists of named organisms. More surveys in natural ecosystems of yet unsurveyed regions in Africa, Asia, Central and South America are needed to unveil the full diversity of the clade and the factors driving diversity, speciation and adaptation in Phytophthora. Taxonomic novelties: New species: Phytophthora amamensis T. Jung, K. Kageyama, H. Masuya & S. Uematsu, Phytophthora angustata T. Jung, L. Garcia, B. Mendieta-Araica, & Y. Balci, Phytophthora balkanensis I. Milenković, Ž. Tomić, T. Jung & M. Horta Jung, Phytophthora borneensis T. Jung, A. Durán, M. Tarigan & M. Horta Jung, Phytophthora calidophila T. Jung, Y. Balci, L. Garcia & B. Mendieta-Araica, Phytophthora catenulata T. Jung, T.-T. Chang, N.M. Chi & M. Horta Jung, Phytophthora celeris T. Jung, L. Oliveira, M. Tarigan & I. Milenković, Phytophthora curvata T. Jung, A. Hieno, H. Masuya & M. Horta Jung, Phytophthora distorta T. Jung, A. Durán, E. Sanfuentes von Stowasser & M. Horta Jung, Phytophthora excentrica T. Jung, S. Uematsu, K. Kageyama & C.M. Brasier, Phytophthora falcata T. Jung, K. Kageyama, S. Uematsu & M. Horta Jung, Phytophthora fansipanensis T. Jung, N.M. Chi, T. Corcobado & C.M. Brasier, Phytophthora frigidophila T. Jung, Y. Balci, K. Broders & I. Milenković, Phytophthora furcata T. Jung, N.M. Chi, I. Milenković & M. Horta Jung, Phytophthora inclinata N.M. Chi, T. Jung, M. Horta Jung & I. Milenković, Phytophthora indonesiensis T. Jung, M. Tarigan, L. Oliveira & I. Milenković, Phytophthora japonensis T. Jung, A. Hieno, H. Masuya & J.F. Webber, Phytophthora limosa T. Corcobado, T. Majek, M. Ferreira & T. Jung, Phytophthora macroglobulosa H.-C. Zeng, H.-H. Ho, F.-C. Zheng & T. Jung, Phytophthora montana T. Jung, Y. Balci, K. Broders & M. Horta Jung, Phytophthora multipapillata T. Jung, M. Tarigan, I. Milenković & M. Horta Jung, Phytophthora multiplex T. Jung, Y. Balci, K. Broders & M. Horta Jung, Phytophthora nimia T. Jung, H. Masuya, A. Hieno & C.M. Brasier, Phytophthora oblonga T. Jung, S. Uematsu, K. Kageyama & C.M. Brasier, Phytophthora obovoidea T. Jung, Y. Balci, L. Garcia & B. Mendieta-Araica, Phytophthora obturata T. Jung, N.M. Chi, I. Milenković & M. Horta Jung, Phytophthora penetrans T. Jung, Y. Balci, K. Broders & I. Milenković, Phytophthora platani T. Jung, A. Pérez-Sierra, S.O. Cacciola & M. Horta Jung, Phytophthora proliferata T. Jung, N.M. Chi, I. Milenković & M. Horta Jung, Phytophthora pseudocapensis T. Jung, T.-T. Chang, I. Milenković & M. Horta Jung, Phytophthora pseudocitrophthora T. Jung, S.O. Cacciola, J. Bakonyi & M. Horta Jung, Phytophthora pseudofrigida T. Jung, A. Durán, M. Tarigan & M. Horta Jung, Phytophthora pseudoccultans T. Jung, T.-T. Chang, I. Milenković & M. Horta Jung, Phytophthora pyriformis T. Jung, Y. Balci, K.D. Boders & M. Horta Jung, Phytophthora sumatera T. Jung, M. Tarigan, M. Junaid & A. Durán, Phytophthora transposita T. Jung, K. Kageyama, C.M. Brasier & H. Masuya, Phytophthora vacuola T. Jung, H. Masuya, K. Kageyama & J.F. Webber, Phytophthora valdiviana T. Jung, E. Sanfuentes von Stowasser, A. Durán & M. Horta Jung, Phytophthora variepedicellata T. Jung, Y. Balci, K. Broders & I. Milenković, Phytophthora vietnamensis T. Jung, N.M. Chi, I. Milenković & M. Horta Jung, Phytophthora ×australasiatica T. Jung, N.M. Chi, M. Tarigan & M. Horta Jung, Phytophthora ×lusitanica T. Jung, M. Horta Jung, C. Maia & I. Milenković, Phytophthora ×taiwanensis T. Jung, T.-T. Chang, H.-S. Fu & M. Horta Jung. Citation: Jung T, Milenković I, Balci Y, Janoušek J, Kudláček T, Nagy ZÁ, Baharuddin B, Bakonyi J, Broders KD, Cacciola SO, Chang T-T, Chi NM, Corcobado T, Cravador A, Đorđević B, Durán A, Ferreira M, Fu C-H, Garcia L, Hieno A, Ho H-H, Hong C, Junaid M, Kageyama K, Kuswinanti T, Maia C, Májek T, Masuya H, Magnano di San Lio G, Mendieta-Araica B, Nasri N, Oliveira LSS, Pane A, Pérez-Sierra A, Rosmana A, Sanfuentes von Stowasser E, Scanu B, Singh R, Stanivuković Z, Tarigan M, Thu PQ, Tomić Z, Tomšovský M, Uematsu S, Webber JF, Zeng H-C, Zheng F-C, Brasier CM, Horta Jung M (2024). Worldwide forest surveys reveal forty-three new species in Phytophthora major Clade 2 with fundamental implications for the evolution and biogeography of the genus and global plant biosecurity. Studies in Mycology 107: 251-388. doi: 10.3114/sim.2024.107.04.
Collapse
Affiliation(s)
- T. Jung
- Mendel University in Brno, Faculty of Forestry and Wood Technology, Department of Forest Protection and Wildlife Management, Phytophthora Research Centre, 613 00 Brno, Czech Republic
- Phytophthora Research and Consultancy, 83131 Nussdorf, Germany
| | - I. Milenković
- Mendel University in Brno, Faculty of Forestry and Wood Technology, Department of Forest Protection and Wildlife Management, Phytophthora Research Centre, 613 00 Brno, Czech Republic
- University of Belgrade, Faculty of Forestry, 11030 Belgrade, Serbia
| | - Y. Balci
- USDA-APHIS Plant Protection and Quarantine, 4700 River Road, Riverdale, Maryland, 20737 USA
| | - J. Janoušek
- Mendel University in Brno, Faculty of Forestry and Wood Technology, Department of Forest Protection and Wildlife Management, Phytophthora Research Centre, 613 00 Brno, Czech Republic
| | - T. Kudláček
- Mendel University in Brno, Faculty of Forestry and Wood Technology, Department of Forest Protection and Wildlife Management, Phytophthora Research Centre, 613 00 Brno, Czech Republic
- University of Greifswald, Institute for Mathematics and Computer Science & Center for Functional Genomics of Microbes, 17489 Greifswald, Germany
| | - Z.Á. Nagy
- Mendel University in Brno, Faculty of Forestry and Wood Technology, Department of Forest Protection and Wildlife Management, Phytophthora Research Centre, 613 00 Brno, Czech Republic
| | - B. Baharuddin
- Departement of Plant Pest and Disease, Faculty of Agriculture, Hasanuddin University, Makassar, 90245, South Sulawesi, Indonesia
| | - J. Bakonyi
- HUN-REN Centre for Agricultural Research, Plant Protection Institute, ELKH, 1022 Budapest, Hungary
| | - K.D. Broders
- Smithsonian Tropical Research Institute, Apartado Panamá, República de Panamá
- USDA, Agricultural Research Service, National Center for Agricultural Utilization Research, Mycotoxin Prevention and Applied Microbiology Research Unit, Peoria, IL, 61604, USA
| | - S.O. Cacciola
- Department of Agriculture, Food and Environment, University of Catania, 95123 Catania, Italy
| | - T.-T. Chang
- Forest Protection Division, Taiwan Forestry Research Institute, Taipei, Taiwan
| | - N.M. Chi
- Forest Protection Research Centre, Vietnamese Academy of Forest Sciences, 10000 Hanoi, Vietnam
| | - T. Corcobado
- Mendel University in Brno, Faculty of Forestry and Wood Technology, Department of Forest Protection and Wildlife Management, Phytophthora Research Centre, 613 00 Brno, Czech Republic
| | - A. Cravador
- MED—Mediterranean Institute for Agriculture, Environment and Development & CHANGE—Global Change and Sustainability Institute, University of Algarve, 8005-130 Faro, Portugal
| | - B. Đorđević
- Mendel University in Brno, Faculty of Forestry and Wood Technology, Department of Forest Protection and Wildlife Management, Phytophthora Research Centre, 613 00 Brno, Czech Republic
| | - A. Durán
- Fiber Research and Development, Asia Pacific Resources International Limited (APRIL), 28300 Pangkalan Kerinci, Riau, Indonesia
| | - M. Ferreira
- Plant Diagnostic Center, Department of Plant Pathology and Crop Physiology, Louisiana State University Agricultural Center, Baton Rouge, Louisiana, USA
| | - C.-H. Fu
- Forest Protection Division, Taiwan Forestry Research Institute, Taipei, Taiwan
| | - L. Garcia
- Universidad Nacional Agraria, Carretera Norte, Managua 11065, Nicaragua
| | - A. Hieno
- River Basin Research Center, Gifu University, Gifu, 501-1193, Japan
| | - H.-H. Ho
- Department of Biology, State University of New York, New Paltz, New York 12561, USA
| | - C. Hong
- Hampton Roads Agricultural Research and Extension Center, Virginia Tech, Virginia Beach, VA 23455, USA
| | - M. Junaid
- Departement of Plant Pest and Disease, Faculty of Agriculture, Hasanuddin University, Makassar, 90245, South Sulawesi, Indonesia
| | - K. Kageyama
- River Basin Research Center, Gifu University, Gifu, 501-1193, Japan
| | - T. Kuswinanti
- Departement of Plant Pest and Disease, Faculty of Agriculture, Hasanuddin University, Makassar, 90245, South Sulawesi, Indonesia
| | - C. Maia
- Centre of Marine Sciences (CCMAR), University of Algarve, 8005-139 Faro, Portugal
| | - T. Májek
- Mendel University in Brno, Faculty of Forestry and Wood Technology, Department of Forest Protection and Wildlife Management, Phytophthora Research Centre, 613 00 Brno, Czech Republic
| | - H. Masuya
- Forestry and Forest Products Research Institute (FFPRI), Tsukuba, Ibaraki, 305-8687, Japan
| | - G. Magnano di San Lio
- University Mediterranea of Reggio Calabria, Department of Agriculture, 89124 Reggio Calabria, Italy
| | | | - N. Nasri
- The United Graduate School of Agricultural Science, Ehime University, Matsuyama, 790-8566, Japan
| | - L.S.S. Oliveira
- Research and Development, Bracell, Alagoinhas, Bahia 48030-300, Brazil
| | - A. Pane
- Department of Agriculture, Food and Environment, University of Catania, 95123 Catania, Italy
| | - A. Pérez-Sierra
- Forest Research, Alice Holt Lodge, Farnham, Surrey GU10 4LH, UK
| | - A. Rosmana
- Departement of Plant Pest and Disease, Faculty of Agriculture, Hasanuddin University, Makassar, 90245, South Sulawesi, Indonesia
| | - E. Sanfuentes von Stowasser
- Laboratorio de Patología Forestal, Facultad Ciencias Forestales y Centro de Biotecnología, Universidad de Concepción, 4030000 Concepción, Chile
| | - B. Scanu
- Department of Agricultural Sciences, University of Sassari, Viale Italia 39A, 07100 Sassari, Italy
| | - R. Singh
- Plant Diagnostic Center, Department of Plant Pathology and Crop Physiology, Louisiana State University Agricultural Center, Baton Rouge, Louisiana, USA
| | - Z. Stanivuković
- University of Banja Luka, Faculty of Forestry, 78000 Banja Luka, Bosnia and Herzegovina
| | - M. Tarigan
- Fiber Research and Development, Asia Pacific Resources International Limited (APRIL), 28300 Pangkalan Kerinci, Riau, Indonesia
| | - P.Q. Thu
- Forest Protection Research Centre, Vietnamese Academy of Forest Sciences, 10000 Hanoi, Vietnam
| | - Z. Tomić
- Center for Plant Protection, Croatian Agency for Agriculture and Food, 10000 Zagreb, Croatia
| | - M. Tomšovský
- Mendel University in Brno, Faculty of Forestry and Wood Technology, Department of Forest Protection and Wildlife Management, Phytophthora Research Centre, 613 00 Brno, Czech Republic
| | - S. Uematsu
- Laboratory of Molecular and Cellular Biology, Dept. of Bioregulation and Bio-interaction, Tokyo University of Agriculture and Technology, Fuchu, Tokyo, 183-8509, Japan
| | - J.F. Webber
- Forest Research, Alice Holt Lodge, Farnham, Surrey GU10 4LH, UK
| | - H.-C. Zeng
- The Institute of Bioscience and Biotechnology, Chinese Academy of Tropical Agricultural Sciences, Haikou 571101, Hainan, China
| | - F.-C. Zheng
- College of Environment and Plant Protection, Hainan University, Baodoa Xincun, Danzhou City, Hainan 571737, China
| | - C.M. Brasier
- Forest Research, Alice Holt Lodge, Farnham, Surrey GU10 4LH, UK
| | - M. Horta Jung
- Mendel University in Brno, Faculty of Forestry and Wood Technology, Department of Forest Protection and Wildlife Management, Phytophthora Research Centre, 613 00 Brno, Czech Republic
- Phytophthora Research and Consultancy, 83131 Nussdorf, Germany
| |
Collapse
|
5
|
Zhao T, Li J, Huang T, Ying ZF, Che YC, Zhao ZM, Fu YT, Tao JH, Yang QH, Wei DK, Li GL, Yi L, Zhao YP, Chen HB, Wang JF, Jiang RJ, Yu L, Cai W, Yang W, Xie MX, Yin QZ, Pu J, Shi L, Hong C, Deng Y, Cai LK, Zhou J, Wen Y, Li HS, Huang W, Mo ZJ, Li CG, Li QH, Yang JS. Immune persistence after different polio sequential immunization schedules in Chinese infants. NPJ Vaccines 2024; 9:50. [PMID: 38424078 PMCID: PMC10904800 DOI: 10.1038/s41541-024-00831-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Accepted: 02/05/2024] [Indexed: 03/02/2024] Open
Abstract
Trivalent oral poliovirus vaccine (tOPV) has been withdrawn and instead an inactivated poliovirus vaccine (IPV) and bivalent type 1 and type 3 OPV (bOPV) sequential immunization schedule has been implemented since 2016, but no immune persistence data are available for this polio vaccination strategy. This study aimed to assess immune persistence following different polio sequential immunization schedules. Venous blood was collected at 24, 36, and 48 months of age from participants who had completed sequential schedules of combined IPV and OPV in phase III clinical trials. The serum neutralizing antibody titers against poliovirus were determined, and the poliovirus-specific antibody-positive rates were evaluated. A total of 1104 participants were enrolled in this study. The positive rates of poliovirus type 1- and type 3-specific antibodies among the sequential immunization groups showed no significant difference at 24, 36, or 48 months of age. The positive rates of poliovirus type 2-specific antibody in the IPV-IPV-tOPV group at all time points were nearly 100%, which was significantly higher than the corresponding rates in other immunization groups (IPV-bOPV-bOPV and IPV-IPV-bOPV). Immunization schedules involving one or two doses of IPV followed by bOPV failed to maintain a high positive rate for poliovirus type 2-specific antibody.
Collapse
Affiliation(s)
- Ting Zhao
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Jing Li
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Teng Huang
- Guangxi Province Center for Disease Control and Prevention, Nanning, China
| | - Zhi-Fang Ying
- National Institutes for Food and Drug Control, Beijing, China
| | - Yan-Chun Che
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Zhi-Mei Zhao
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Yu-Ting Fu
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Jun-Hui Tao
- Liujiang District Center for Disease Prevention and Control, Liuzhou, China
| | - Qing-Hai Yang
- Liucheng County Center for Disease Prevention and Control, Liuzhou, China
| | - Ding-Kai Wei
- Rongan County Center for Disease Prevention and Control, Liuzhou, China
| | - Guo-Liang Li
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Li Yi
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Yu-Ping Zhao
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Hong-Bo Chen
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Jian-Feng Wang
- National Institutes for Food and Drug Control, Beijing, China
| | - Rui-Ju Jiang
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Lei Yu
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Wei Cai
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Wei Yang
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Ming-Xue Xie
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Qiong-Zhou Yin
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Jing Pu
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Li Shi
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Chao Hong
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Yan Deng
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Lu-Kui Cai
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Jian Zhou
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Yu Wen
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Hong-Sen Li
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Wei Huang
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China
| | - Zhao-Jun Mo
- Guangxi Province Center for Disease Control and Prevention, Nanning, China.
| | - Chang-Gui Li
- National Institutes for Food and Drug Control, Beijing, China.
| | - Qi-Han Li
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China.
| | - Jing-Si Yang
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China.
| |
Collapse
|
6
|
Guo WL, Hou P, Tan WG, Lei YX, Wu XF, Huang HQ, Hong C. [A case of metastatic breast cancer complicated by pulmonary tumor thrombotic microangiopathy]. Zhonghua Jie He He Hu Xi Za Zhi 2023; 46:1014-1018. [PMID: 37752045 DOI: 10.3760/cma.j.cn112147-20230521-00253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/28/2023]
Abstract
Pulmonary tumor thrombotic microangiopathy is a malignancy-related complication with rapid progression and high mortality. To improve the understanding of the disease, early diagnosis and treatment are key to successful treatment. A 39-year-old patient with pulmonary hypertension transferred from another hospital was admitted to the First Affiliated Hospital of Guangzhou Medical University on September 26, 2021. The patient developed shortness of breath and progressive exacerbation over the past month. No pulmonary artery embolism was seen on computed tomography pulmonary angiography (CTPA) at the outside hospital where the breast cancer was diagnosed. Pulmonary tumor thrombotic microangiopathy was immediately considered on admission and oncological endocrine therapy was started. After treatment, the patient's dyspnoea improved, PET-CT showed significant tumor regression, and cardiac ultrasound showed a significant decrease in pulmonary artery pressure. The successful treatment experience of this case was summarized for reference.
Collapse
Affiliation(s)
- W L Guo
- State Key Laboratory of Respiratory Diseases/National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Department of Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510163, China
| | - P Hou
- State Key Laboratory of Respiratory Diseases/National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510163, China
| | - W G Tan
- State Key Laboratory of Respiratory Diseases/National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Department of Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510163, China
| | - Y X Lei
- State Key Laboratory of Respiratory Diseases/National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Department of Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510163, China
| | - X F Wu
- State Key Laboratory of Respiratory Diseases/National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Department of Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510163, China
| | - H Q Huang
- State Key Laboratory of Respiratory Diseases/National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Department of Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510163, China
| | - C Hong
- State Key Laboratory of Respiratory Diseases/National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Department of Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510163, China
| |
Collapse
|
7
|
Shi M, Mi X, Huang L, Qiu L, Yang L, Sun X, Hong C, Yang Y, Wang X, Liu GQ. Nondestructive and Quantitative Analysis of Cell Wall Regeneration in the Medicinal Macrofungus Ganoderma lingzhi by a Membrane-Fusing Fluorescent Probe. Anal Chem 2023; 95:8357-8366. [PMID: 37202872 DOI: 10.1021/acs.analchem.3c01016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/20/2023]
Abstract
Ganoderma is a prize medicinal macrofungus with a broad range of pharmaceutical values. To date, various attempts have been made to cultivate Ganoderma to improve the production of secondary metabolites with pharmacological activity. Among the adopted techniques, protoplast preparation and regeneration are indispensable. However, the evaluation of protoplasts and regenerated cell walls usually relies on electron microscopy assays, which require time-consuming and destructive sample preparation and merely provide localized information in the selected area. In contrast, fluorescence assays enable sensitive real-time detection and imaging in vivo. They can also be applied to flow cytometry, providing a collective overview of every cell in a sample. However, for macrofungi such as Ganoderma, the fluorescence analysis of protoplasts and regenerated cell walls is difficult owing to the hindrance of the homologous fluorescent protein expression and the lack of an appropriate fluorescence marker. Herein, a specific plasma membrane probe, TAMRA perfluorocarbon nucleic acid probe (TPFN), is proposed for the nondestructive and quantitative fluorescence analysis of cell wall regeneration. Exploiting the perfluorocarbon membrane-anchoring chains, hydrophilic nucleic acid linker, and fluorescent dye TAMRA, the probe is proven to be selective, soluble, and stable, enabling rapid fluorescence detection of a protoplast sample free of transgenic expression or immune staining. Based on the TPFN and flow cytometry techniques, a quantitative approach is constructed to monitor the process of cell wall growth in a fast, quantitative, and high-throughout manner, and the obtained results are consistent with those of conventional electron microscopy. In principle, with slight modifications or integration, the proposed probe and approach can be adapted to the preparation of cell protoplasts, inspection of cell wall integrity under environmental stress, and programmable membrane engineering for cytobiology and physiology research.
Collapse
Affiliation(s)
- Muling Shi
- Hunan Provincial Key Laboratory of Forestry Biotechnology & International Cooperation Base of Science and Technology Innovation on Forest Resource Biotechnology, Yuelu Mountain Hunan Provincial Laboratory, Central South University of Forestry & Technology, Changsha, Hunan 410004, China
- Molecular Science and Biomedicine Laboratory, State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Collaborative Innovation Center for Chemistry and Molecular Medicine, Hunan University, Changsha 410082, China
- College of Materials Science and Engineering, Hainan University, Haikou, Hainan 570228, China
| | - Xujun Mi
- Hunan Provincial Key Laboratory of Forestry Biotechnology & International Cooperation Base of Science and Technology Innovation on Forest Resource Biotechnology, Yuelu Mountain Hunan Provincial Laboratory, Central South University of Forestry & Technology, Changsha, Hunan 410004, China
| | - Ling Huang
- Hunan Provincial Key Laboratory of Forestry Biotechnology & International Cooperation Base of Science and Technology Innovation on Forest Resource Biotechnology, Yuelu Mountain Hunan Provincial Laboratory, Central South University of Forestry & Technology, Changsha, Hunan 410004, China
| | - Liping Qiu
- Molecular Science and Biomedicine Laboratory, State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Collaborative Innovation Center for Chemistry and Molecular Medicine, Hunan University, Changsha 410082, China
| | - Liu Yang
- Molecular Science and Biomedicine Laboratory, State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Collaborative Innovation Center for Chemistry and Molecular Medicine, Hunan University, Changsha 410082, China
| | - Xing Sun
- Molecular Science and Biomedicine Laboratory, State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Collaborative Innovation Center for Chemistry and Molecular Medicine, Hunan University, Changsha 410082, China
| | - Chao Hong
- College of Materials Science and Engineering, Hainan University, Haikou, Hainan 570228, China
| | - Yingzhuo Yang
- Hunan Provincial Key Laboratory of Forestry Biotechnology & International Cooperation Base of Science and Technology Innovation on Forest Resource Biotechnology, Yuelu Mountain Hunan Provincial Laboratory, Central South University of Forestry & Technology, Changsha, Hunan 410004, China
| | - Xiaoling Wang
- Hunan Provincial Key Laboratory of Forestry Biotechnology & International Cooperation Base of Science and Technology Innovation on Forest Resource Biotechnology, Yuelu Mountain Hunan Provincial Laboratory, Central South University of Forestry & Technology, Changsha, Hunan 410004, China
| | - Gao-Qiang Liu
- Hunan Provincial Key Laboratory of Forestry Biotechnology & International Cooperation Base of Science and Technology Innovation on Forest Resource Biotechnology, Yuelu Mountain Hunan Provincial Laboratory, Central South University of Forestry & Technology, Changsha, Hunan 410004, China
| |
Collapse
|
8
|
Cui H, Zeng L, Li R, Li Q, Hong C, Zhu H, Chen L, Liu L, Zou X, Xiao L. Radiomics signature based on CECT for non-invasive prediction of response to anti-PD-1 therapy in patients with hepatocellular carcinoma. Clin Radiol 2023; 78:e37-e44. [PMID: 36257868 DOI: 10.1016/j.crad.2022.09.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2022] [Revised: 08/07/2022] [Accepted: 09/02/2022] [Indexed: 01/18/2023]
Abstract
PURPOSE This study aimed to develop a radiomics signature (RS) based on contrast-enhanced computed tomography (CECT) and evaluate its potential predictive value in hepatocellular carcinoma (HCC) patients receiving anti-PD-1 therapy. METHOD CECT scans of 76 HCC patients who received anti-PD-1 therapy were obtained in this study (training group = 53 and validation group = 23). The least absolute shrinkage and selection operator (LASSO) regression was applied to select radiomics features of primary and metastatic lesions and establish a RS to predict lesion-level response. Then, a nomogram combined the mean RS (MRS) and clinical variables with patient-level response as the end point. RESULTS In the lesion-level analysis, the area under the curves (AUCs) of RS in the training and validation groups were 0.751 (95% CI, 0.668-0.835) and 0.734 (95% CI, 0.604-0.864), respectively. In the patient-level analysis, the AUCs of the nomogram in the training and validation groups were 0.897 (95% CI, 0.798-0.996) and 0.889 (95% CI, 0.748-1.000), respectively. The nomogram stratified patients into low- and high-risk groups, which showed a significant difference in progression-free survival (PFS) (p<0.05). CONCLUSIONS The RS is a noninvasive biomarker for predicting anti-PD-1 therapy response in patients with HCC. The nomogram may be of clinical use for identifying high-risk patients and formulating individualised treatments.
Collapse
Affiliation(s)
- H Cui
- Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
| | - L Zeng
- Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
| | - R Li
- Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
| | - Q Li
- Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
| | - C Hong
- Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
| | - H Zhu
- Department of Medical Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China
| | - L Chen
- Department of Medical Quality Management, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
| | - L Liu
- Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
| | - X Zou
- Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
| | - L Xiao
- Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
| |
Collapse
|
9
|
Chen Z, Li J, Zheng J, Jin Y, Zhang Y, Tang F, Li J, Cheng H, Jiang L, Wen H, Hong C, Zeng X, Huang S, Lu B, Li L, Wang Z. Emerging Omicron subvariants evade neutralizing immunity elicited by vaccine or BA.1/BA.2 infection. J Med Virol 2023; 95:e28539. [PMID: 36719034 DOI: 10.1002/jmv.28539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Revised: 01/18/2023] [Accepted: 01/25/2023] [Indexed: 02/01/2023]
Abstract
The newly emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2.75 and BA.2.76 subvariants contained 35 and 29 additional mutations in its spike (S) protein compared with the reference SARS-CoV-2 genome, respectively. Here, we measured the evasion degree of the BA.1, BA.2, BA.4, BA.5, BA.2.75, and BA.2.76 subvariants from neutralizing immunity in people previously infected with the Omicron BA.1 and BA.2, determined the effect of vaccination on immune evasion, and compared the titers of neutralizing antibodies in serums between acute infection and convalescence. Results showed that the neutralization effect of serums from patients with different vaccination statuses and BA.1/BA.2 breakthrough infection decreased with the Omicron evolution from BA.1 to BA.2, BA.4, BA.5, BA.2.75, and BA.2.76. This study also indicated that the existing vaccines could no longer provide effective protection, especially for the emerging BA.2.75 and BA.2.76 subvariants. Therefore, vaccines against emerging epidemic strains should be designed specifically. In the future, we can not only focus on the current strains, but also predict and design new vaccines against potential mutant strains. At the same time, we can combine the virus strains' infection characteristics to develop protective measures for virus colonization areas, such as nasal protection spray. Besides, further studies on the Y248N mutation of BA.2.76 subvariant were also necessary to explore its contribution to the enhanced immune evasion ability.
Collapse
Affiliation(s)
- Zehui Chen
- Xiamen Center for Disease Control and Prevention, Xiamen, China
| | - Jiaming Li
- Beijing Institute of Biotechnology, Beijing, China
| | - Jing Zheng
- Xiamen Center for Disease Control and Prevention, Xiamen, China
| | - Yifei Jin
- Beijing Institute of Biotechnology, Beijing, China
| | - Yidun Zhang
- Xiamen Center for Disease Control and Prevention, Xiamen, China
| | - Fei Tang
- Xiamen Center for Disease Control and Prevention, Xiamen, China
| | - Jingjing Li
- Beijing Institute of Biotechnology, Beijing, China
| | | | - Lina Jiang
- Xiamen Center for Disease Control and Prevention, Xiamen, China
| | - Huixin Wen
- Xiamen Center for Disease Control and Prevention, Xiamen, China
| | - Chao Hong
- Xiamen Center for Disease Control and Prevention, Xiamen, China
| | - Xiaohong Zeng
- Xiamen Center for Disease Control and Prevention, Xiamen, China
| | - Shijie Huang
- Xiamen Center for Disease Control and Prevention, Xiamen, China
| | - Bing Lu
- Beijing Institute of Biotechnology, Beijing, China
| | - Li Li
- Xiamen Center for Disease Control and Prevention, Xiamen, China
| | - Zhongyi Wang
- Beijing Institute of Biotechnology, Beijing, China
| |
Collapse
|
10
|
Loo G, Yap J, Hon JS, Ismail A, Lim CL, Sumanthy P, Ruan W, Sewa DW, Phua GC, Ng SA, Hong C, Low A, Lim ST, Tan JL. Real-world outcomes of Selexipag for treatment of pulmonary hypertension in an Asian population. Eur Heart J 2023. [DOI: 10.1093/eurheartj/ehac779.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction
Selexipag is an oral selective prostacyclin IP receptor agonist indicated for treatment of pulmonary arterial hypertension (PAH). Data on its real-world safety and efficacy in Asians is lacking.
Purpose
We sought to evaluate the clinical characteristics, treatment regimens and outcomes of patients initiated on selexipag in a tertiary cardiac centre in Asia.
Methods
This was a retrospective study on all patients initiated on selexipag from January 2017 to December 2020. Baseline and follow up characteristics including demographics, functional status and clinical data were collected. Clinical outcomes evaluated included hospitalisation for PH related complications and all-cause mortality. Patients were risk stratified using the COMPERA 2.0 risk scores.
Results
A total of 36 PAH patients were treated with selexipag. At baseline, most patients were WHO functional class II or III (36.4% and 51.5% respectively), with a NT-proBNP of 1335 pg/ml (557 – 2918) and 6 minute walk test (6MWT) duration of 327.5 ±126.4 meters. Selexipag was initiated at 200mcg twice daily dosage for all except one patient (started at 200mcg once daily) and the maximum tolerated dose ranged from 200mcg twice daily to 1400mcg twice daily, with majority tolerating up to a dose of 600mcg twice daily (58.3%). Side effects were reported in 23 patients (63.9%), of which headache (27.8%), diarrhea (30.6%) or musculoskeletal symptoms (27.8%) were predominant. After a median follow up duration of 25.9 ± 23.1 months, selexipag was stopped in 20 patients (55.6%), of which eight patients were due to PAH progression requiring alternative therapy, and 12 patients due to side effects from selexipag. At baseline, patients were classified into low (8.3%), intermediate-low (30.6%), intermediate-high (33.3%) and high risk (27.8%) respectively. Patients who continued on selexipag at follow up showed no change (46.2%), improvement (15.4%) and deterioration (38.5%) in risk score. In the overall cohort of 36 patients, majority (75%) had at least one hospitalisation for PAH related complications and 15 patients (41.7%) demised.
Conclusion
In this real-world study, while selexipag was associated with a stable or improved PAH risk scores in majority of patients, there was a subset of patients with disease progression or intolerance to the medication. Further studies are warranted to identify patients who will benefit most from this therapy.
Collapse
Affiliation(s)
- G Loo
- National Heart Centre Singapore , Singapore , Singapore
| | - J Yap
- National Heart Centre Singapore , Singapore , Singapore
| | - J S Hon
- National Heart Centre Singapore , Singapore , Singapore
| | - A Ismail
- National Heart Centre Singapore , Singapore , Singapore
| | - C L Lim
- National Heart Centre Singapore , Singapore , Singapore
| | - P Sumanthy
- National Heart Centre Singapore , Singapore , Singapore
| | - W Ruan
- National Heart Centre Singapore , Singapore , Singapore
| | - D W Sewa
- Singapore General Hospital , Singapore , Singapore
| | - G C Phua
- Singapore General Hospital , Singapore , Singapore
| | - S A Ng
- Singapore General Hospital , Singapore , Singapore
| | - C Hong
- Singapore General Hospital , Singapore , Singapore
| | - A Low
- Singapore General Hospital , Singapore , Singapore
| | - S T Lim
- National Heart Centre Singapore , Singapore , Singapore
| | - J L Tan
- National Heart Centre Singapore , Singapore , Singapore
| |
Collapse
|
11
|
Li J, Zheng J, Chen P, Wang B, Zhang Y, Xiong J, You L, Jin Y, Jiang L, Tang F, Wen H, Hong C, Zeng X, Li L, Lu B, Rong B, Wang Z. Higher SARS-CoV-2 shedding in exhaled aerosol probably contributed to the enhanced transmissibility of Omicron BA.5 subvariant. J Med Virol 2023; 95:e28365. [PMID: 36458536 PMCID: PMC9877788 DOI: 10.1002/jmv.28365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Revised: 10/22/2022] [Accepted: 11/28/2022] [Indexed: 12/03/2022]
Affiliation(s)
- Jiaming Li
- Beijing Institute of BiotechnologyBeijingChina
| | - Jing Zheng
- Xiamen Center for Disease Control and PreventionXiamenChina
| | - Peng Chen
- Xinglin Branch of the First Affiliated Hospital of Xiamen UniversityXiamenChina
| | - Baochun Wang
- First Affiliated Hospital of Xiamen UniversityXiamenChina
| | - Yidun Zhang
- Xiamen Center for Disease Control and PreventionXiamenChina
| | - Jinwei Xiong
- Xinglin Branch of the First Affiliated Hospital of Xiamen UniversityXiamenChina
| | - Liuping You
- Xinglin Branch of the First Affiliated Hospital of Xiamen UniversityXiamenChina
| | - Yifei Jin
- Beijing Institute of BiotechnologyBeijingChina
| | - Lina Jiang
- Xiamen Center for Disease Control and PreventionXiamenChina
| | - Fei Tang
- Xiamen Center for Disease Control and PreventionXiamenChina
| | - Huixin Wen
- Xiamen Center for Disease Control and PreventionXiamenChina
| | - Chao Hong
- Xiamen Center for Disease Control and PreventionXiamenChina
| | - Xiaohong Zeng
- Xiamen Center for Disease Control and PreventionXiamenChina
| | - Li Li
- Xiamen Center for Disease Control and PreventionXiamenChina
| | - Bing Lu
- Beijing Institute of BiotechnologyBeijingChina
| | - Biao Rong
- Xiamen Center for Disease Control and PreventionXiamenChina
| | | |
Collapse
|
12
|
Hong C, Li L, Zou JY, Zhang L, You SY. A turn-on fluorescent Zn(II) metal−organic framework sensor for quantitative anthrax biomarker detection. Dalton Trans 2023; 52:6067-6076. [PMID: 37060132 DOI: 10.1039/d3dt00619k] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
Abstract
2, 6-pyridine dicarboxylic acid (DPA) is considered as one of the main anthrax biomarkers, and the detection of DPA is of great significance. This work presented a Zn(II) based metal-organic...
Collapse
Affiliation(s)
- Chao Hong
- Institute of Applied Chemistry, Jiangxi Academy of Sciences, Nanchang 330096, PR China.
- School of Materials Science and Engineering, Nanchang Hangkong University, Nanchang, 330063, PR China
| | - Ling Li
- Institute of Applied Chemistry, Jiangxi Academy of Sciences, Nanchang 330096, PR China.
| | - Ji-Yong Zou
- Institute of Applied Chemistry, Jiangxi Academy of Sciences, Nanchang 330096, PR China.
| | - Li Zhang
- Institute of Applied Chemistry, Jiangxi Academy of Sciences, Nanchang 330096, PR China.
| | - Sheng-Yong You
- Institute of Applied Chemistry, Jiangxi Academy of Sciences, Nanchang 330096, PR China.
| |
Collapse
|
13
|
Yoon A, Faldu J, Hong C. Craniofacial Growth Modification Protocol for Pediatric OSA. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Yoon A, Bockow R, Abdelwahab M, Vakili A, Lovell K, Ganguly R, Liu S, Kushida C, Hong C. Impact of Rapid Maxillary Expansion on Adenotonsillar Hypertrophy in Children. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
15
|
Santiago S, Hong C, As-Sanie S, Till S. 8258 Does Uterine Size Matter? the Relationship between Surgeon Volume, Surgical Approach, and Uterine Weight for Benign Hysterectomy. J Minim Invasive Gynecol 2022. [DOI: 10.1016/j.jmig.2022.09.391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Paller A, Blauvelt A, Soong W, Hong C, Schuttelaar M, Schneider S, Moerch M, Simpson E. MEANINGFUL RESPONSES IN TRALOKINUMAB-TREATED ADOLESCENTS WITH ATOPIC DERMATITIS NOT ACHIEVING IGA 0/1 AT WEEK-16. Ann Allergy Asthma Immunol 2022. [DOI: 10.1016/j.anai.2022.08.715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
17
|
Hong C, Li H, Parel PM, Berg AR, Rodante J, Keel A, Teague HL, Playford MP, Chen MY, Zhou W, Sorokin AV, Bluemke DA, Mehta NN. Application of machine learning to identify top determinants of fibrofatty plaque burden by CCTA in humans with psoriasis. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Fibrofatty plaque burden (FFB) is a high-risk, vulnerable plaque feature comprised of an atheromatous core and fibrous cap with increased risk of coronary artery disease (CAD) [1]. Psoriasis (PSO) is a chronic inflammatory disease linked with atherosclerotic risk and premature cardiovascular disease, driven in part by vulnerable plaque rupture [2,3]. Machine learning (ML) previously showed the prognostic value of FFB in predicting 5-year risk of cardiac-related mortality in patients with CAD [4]. Whether ML can predict FFB in psoriasis is understudied.
Purpose
To use ML to identify top determinants of FFB by CCTA in PSO.
Methods
320 consecutive participants with psoriasis were recruited as part of an ongoing cohort study, of whom 307 had FFB analyzed with coronary computed tomography angiography (CCTA) and quantified by QAngio CT (Medis, The Netherlands). 140 out of 182 potential determinants were subjected to ML algorithms analyzed by random forest and validated by 5-fold cross validation to select the top determinants based on R-square criteria. Lipid concentration and size were measured by nuclear magnetic resonance (NMR) and sdLDL-C was calculated by Sampson's formula.
Results
The top 21 determinants of FFB at baseline were grouped into 3 categories: cardiometabolic risk factors (BMI, sex, DBP, mean arterial pressure, exercise, heart rate, glucose, anxiety, psoriasis disease duration), clinical measurements (basophils, platelets, hemoglobin, RBC, alkaline phosphatase, ALT, creatinine, neutrophil-to-lymphocyte ratio), and lipoproteins (LDL particle size, apolipoprotein A1, apolipoprotein B-to-A1 ratio, calculated sdLDL-C).
Conclusion
ML confirmed that FFB strongly correlates with cardiometabolic risk factors, clinical measurements, and lipoproteins. Further investigations into these top determinants of FFB over time may provide insight into potential therapeutic interventions that decrease cardiovascular risk in patients with chronic inflammatory diseases and should be validated in larger studies.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): This study was supported by the National Heart, Lung and Blood Institute (NHLBI) IntramuralResearch Program (ZIA-HL-06193). This research was made possible through the NIH MedicalResearch Scholars Program, a public-private partnership supported jointly by the NIH andcontributions to the Foundation for the NIH from the Doris Duke Charitable Foundation,Genentech, the American Association for Dental Research, the Colgate-Palmolive Company, andother private donors.
Collapse
Affiliation(s)
- C Hong
- National Heart Lung and Blood Institute , Bethesda , United States of America
| | - H Li
- National Heart Lung and Blood Institute , Bethesda , United States of America
| | - P M Parel
- National Heart Lung and Blood Institute , Bethesda , United States of America
| | - A R Berg
- National Heart Lung and Blood Institute , Bethesda , United States of America
| | - J Rodante
- National Heart Lung and Blood Institute , Bethesda , United States of America
| | - A Keel
- National Heart Lung and Blood Institute , Bethesda , United States of America
| | - H L Teague
- National Heart Lung and Blood Institute , Bethesda , United States of America
| | - M P Playford
- National Heart Lung and Blood Institute , Bethesda , United States of America
| | - M Y Chen
- National Heart Lung and Blood Institute , Bethesda , United States of America
| | - W Zhou
- National Heart Lung and Blood Institute , Bethesda , United States of America
| | - A V Sorokin
- National Heart Lung and Blood Institute , Bethesda , United States of America
| | - D A Bluemke
- University of Wisconsin-Madison, Department of Radiology , Madison , United States of America
| | - N N Mehta
- National Heart Lung and Blood Institute , Bethesda , United States of America
| |
Collapse
|
18
|
Hong C, Wang E, Turgeon R, Wong G. COMPARING DUAL ANTIPLATELET THERAPY STRATEGIES POST-ACUTE CORONARY SYNDROME: NETWORK META-ANALYSIS. Can J Cardiol 2022. [DOI: 10.1016/j.cjca.2022.08.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
19
|
Xia J, Zhang S, Zhang R, Wang A, Zhu Y, Dong M, Ma S, Hong C, Liu S, Wang D, Wang J. Targeting therapy and tumor microenvironment remodeling of triple-negative breast cancer by ginsenoside Rg3 based liposomes. J Nanobiotechnology 2022; 20:414. [PMID: 36109762 PMCID: PMC9479350 DOI: 10.1186/s12951-022-01623-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Accepted: 09/01/2022] [Indexed: 11/10/2022] Open
Abstract
The chemotherapy effect of docetaxel (DTX) against triple-negative breast cancer (TNBC) remains mediocre and limited when encapsulated in conventional cholesterol liposomes, mainly ascribed to poor penetration and immunosuppressive tumor microenvironment (TME) caused by tumor stroma cells, especially cancer-associated fibroblasts (CAFs). Many studies have attempted to address these problems but trapped into the common dilemma of excessively complicated formulation strategies at the expense of druggability as well as clinical translational feasibility. To better address the discrepancy, ginsenoside Rg3 was utilized to substitute cholesterol to develop a multifunctional DTX-loaded Rg3 liposome (Rg3-Lp/DTX). The obtained Rg3-Lp/DTX was proved to be preferentially uptake by 4T1 cells and accumulate more at tumor site via the interaction between the glycosyl moiety of Rg3 exposed on liposome surface and glucose transporter1 (Glut1) overexpressed on tumor cells. After reaching tumor site, Rg3 was shown to reverse the activated CAFs to the resting stage and attenuate the dense stroma barrier by suppressing secretion of TGF-β from tumor cells and regulating TGF-β/Smad signaling. Therefore, reduced levels of CAFs and collagens were found in TME after incorporation of Rg3, inducing enhanced penetration of Rg3-Lp/DTX in the tumor and reversed immune system which can detect and neutralize tumor cells. Compared with wooden cholesterol liposomes, the smart and versatile Rg3-Lp/DTX could significantly improve the anti-tumor effect of DTX, providing a promising approach for TNBC therapy with excellent therapeutic efficacy and simple preparation process.
Collapse
|
20
|
Hong C, Yu S, Liu Z, Xu Z, Zhang Y. Synthesis of Furans via Rhodium(III)-Catalyzed Cyclization of Acrylic Acids with α-Diazocarbonyl Compounds. J Org Chem 2022; 87:11979-11988. [PMID: 36037102 DOI: 10.1021/acs.joc.2c00924] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
An efficient protocol for the synthesis of furans through Rh(III)-catalyzed vinyl C-H activation from acrylic acids and α-diazocarbonyl compounds has been developed. The reaction features broad functional group tolerance and affords a series of furans in moderate to good yields. Moreover, no additives such as copper or silver salts are required. Some control experiments are performed to give insight into the mechanism of this cascade transformation and the decarbonylation process is involved in the formation of the furan product.
Collapse
Affiliation(s)
- Chao Hong
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Shuling Yu
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Zhanxiang Liu
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Zijing Xu
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Yuhong Zhang
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China.,State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, China
| |
Collapse
|
21
|
Gonzalez-Cantero Á, Patel N, Hong C, Abbad-Jaime de Aragón C, Berna-Rico E, Solis J, Ballester A, Sorokin A, Teague H, Playford M, Barderas M, Fernandez-Friera L, Mehta N. 845 HDL composition, particle number and size is associated with non-calcified coronary plaque in psoriasis. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Lin E, Tu H, Hong C. 160 Halved incidence of scrub typhus after travel restriction to confine a surge of COVID-19 in Taiwan in 2021. J Invest Dermatol 2022. [PMCID: PMC9296970 DOI: 10.1016/j.jid.2022.05.167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
23
|
Hong C, Lu H, Huang X, Chen M, Jin R, Dai X, Gong F, Dong H, Wang H, Gao XM. Neutrophils as regulators of macrophage-induced inflammation in a setting of allogeneic bone marrow transplantation. Stem Cell Reports 2022; 17:1561-1575. [PMID: 35777356 PMCID: PMC9287675 DOI: 10.1016/j.stemcr.2022.05.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Revised: 05/30/2022] [Accepted: 05/31/2022] [Indexed: 11/26/2022] Open
Abstract
Clinical data reveal that patients with allogeneic hematopoietic stem cell transplantation (HSCT) are vulnerable to infection and prone to developing severe sepsis, which greatly compromises the success of transplantation, indicating a dysregulation of inflammatory immune response in this clinical setting. Here, by using a mouse model of haploidentical bone marrow transplantation (haplo-BMT), we found that uncontrolled macrophage inflammation underlies the pathogenesis of both LPS- and E.coli-induced sepsis in recipient animals with graft-versus-host disease (GVHD). Deficient neutrophil maturation in GVHD mice post-haplo-BMT diminished modulation of macrophage-induced inflammation, which was mechanistically dependent on MMP9-mediated activation of TGF-β1. Accordingly, adoptive transfer of mature neutrophils purified from wild-type donor mice inhibited both sterile and infectious sepsis in GVHD mice post-haplo-BMT. Together, our findings identify a novel mature neutrophil-dependent regulation of macrophage inflammatory response in a haplo-BMT setting and provide useful clues for developing clinical strategies for patients suffering from post-HSCT sepsis. Macrophage inflammation leads to the development of post-haplo-BMT sepsis Impaired neutrophil maturation diminishes regulation of macrophage inflammation Extramedullary granulopoiesis fails to support neutrophil maturation after haplo-BMT Neutrophils regulate macrophage inflammation via MMP9-mediated TGF-β1 activation
Collapse
Affiliation(s)
- Chao Hong
- Institutes of Biology and Medical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China.
| | - Hongyun Lu
- Institutes of Biology and Medical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China
| | - Xiaohong Huang
- Institutes of Biology and Medical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China
| | - Ming Chen
- Institutes of Biology and Medical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China
| | - Rong Jin
- Institutes of Biology and Medical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China
| | - Xiaoqiu Dai
- Institutes of Biology and Medical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China
| | - Fangyuan Gong
- Institutes of Biology and Medical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China
| | - Hongliang Dong
- Institutes of Biology and Medical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China
| | - Hongmin Wang
- Institutes of Biology and Medical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China
| | - Xiao-Ming Gao
- Institutes of Biology and Medical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China.
| |
Collapse
|
24
|
Abstract
The efficient synthesis of pyranones is presented by a three-component cascade reaction from readily available acrylic acids, ethyl glyoxylate, and p-toluenesulfonamide under ruthenium catalysis. For the first time, the nucleophilic addition of the vinylic C-H bond of acrylic acids across aldehyde is achieved, and the intramolecular cyclization as well as subsequent second insertion to aldehyde form the substituted butenolides. The elimination of sulfonamides occurs at higher temperature to give the pyranones.
Collapse
Affiliation(s)
- Shuling Yu
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Chao Hong
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Zhanxiang Liu
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Yuhong Zhang
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China.,State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, China
| |
Collapse
|
25
|
Hong C, Fang L, Yeo YW, Lee HY, Low A, Leung YY. AB0932 Patient and learner experience in a new set up of a rheum-derm combined care model for psoriatic arthritis. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPsoriasis (PsO) and musculoskeletal manifestations are common among patients with psoriatic arthritis (PsA). A shared-care model between rheumatologists and dermatologists has been advocated to promote early diagnosis and improve management care. Data from Asia is scanty. Patients’ and learners’ experience of shared-care models are seldom explored.ObjectivesWe described the set-up of a new shared-cared PsA-PsO clinic incorporating service, education and research between rheumatologist and dermatologist for PsA. We describe the patients’ and learners’ experience of this shared-care model.MethodsA combined care clinic was newly set up in 2019. Referrals were internal through either specialty. Each patient was first seen by a trainee, followed by both a dermatologist and rheumatologist simultaneously in the same consultation room. We collected patients’ and learners’ experience through self-administered survey.ResultsFrom May 2019 to January 2020, data from 44 visits (55% new referrals, 45% follow-up) from 28 patients were captured in the PsA-PsO clinic. 50% of cases were referred from either specialty. 34% were referred for diagnostic doubts, 66% were for therapeutic issues. 61% of patients continued follow-up in the PsA-PsO clinic, and 39% discharged back to respective care. From patients’ experience rated on scale from 0-10, median (interquartile range, IQR) rating of the care was 8 (7, 8). 69.2% and 96% of patients would recommend the care to others. Free text comments included enhanced convenience, time saving, and having both specialties input on management. From 20 learners (3 medial students, 12 residents, 4 senior residents and one scientist), 95% reported extremely or very beneficial to training, 77.8% reported improved confidence in care for PsA and/or PsO patients. The PsA-PsO clinic was temporally suspended during the Covid-19 viral pandemic since February 2020 due to lack of manpower and not fulfilling the spacing out requirement for infectious control. The service was resumed gradually from May 2021.ConclusionDespite challenges, we report the setup of a new care model between dermatologists and rheumatologists for care of patients with psoriatic disease. The care model was well received by patients. Learners from various levels reported benefit from the learning experience.Disclosure of InterestsCassandra Hong: None declared, Liwen Fang: None declared, Yi-Wei Yeo: None declared, Haur Yueh Lee: None declared, Andrea Low: None declared, Ying Ying Leung Speakers bureau: Received honorarium from Abbvie, DKSH, Janssen, Novartis and Pfizer.
Collapse
|
26
|
Tan YK, Hong C, LI H, Allen JC, Thumboo J. AB1328 A FEASIBILITY STUDY ON A NOVEL COMBINED THERMAL IMAGING AND CLINICAL JOINT ASSESSMENT APPROACH USING ULTRASOUND DETECTED JOINT INFLAMMATION OUTCOMES IN RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundThermal imaging (TI) is a portable, low cost imaging tool with high feasibility for use. Clinical joint assessment.Is routinely performed in rheumatoid arthritis (RA) patient care.ObjectivesTo assess a combined TI and clinical joint assessment (CTCA) approach in comparison with TI alone using ultrasound (US) detected joint inflammation outcomes as a gold standard.MethodsBilateral (BL) hand and wrist (22 joint sites) were assessed in this cross-sectional study. For TI (performed in a draft free room with a controlled temperature of around 22°C), the adjusted maximum (Tmax), minimum (Tmin) and average (Tavg) temperatures were derived by subtracting a control temperature (lowest Tmin at the joints per subject) from the Tmax, Tmin and Tavg per joint. US power Doppler (PD) and greyscale (GS) joint inflammation were graded semi-quantitatively (0-3) using validated scoring methods. Joint swelling and tenderness were graded as yes = 1 or no = 0. To increase the relative weightage of CTCA-MAX, CTCA-MIN and CTCA-AVG on the CTCA scores, if the joint was swollen and/or tender, the adjusted Tmax, Tmin and Tavg at each joint were multiplied by a factor of 2; otherwise, they remained unchanged. Receiver operating characteristic (ROC) analysis assessed the performance of TI and CTCA in identifying joints with US PD score > 1 and GS score > 1. A parameter was selected as a univariate predictor if statistically significant (P < 0.05) with area under the ROC curve (AUC) ≥ 0.70.ResultsThis study included 814 joints from 37 RA patients (mean disease duration, 30.9 months; mean DAS28, 4.43). For both TI and CTCA, out of the 22 joints sites, 3 joint sites were evaluated for PD score > 1 and 14 joint sites for GS score > 1; the remaining joint sites had AUC results unavailable due to small number of outcomes. For TI (Table 1), 3 joint sites had ≥ 1 predictive parameter for either PD score > 1 and/or GS score > 1 as follows: left (L) wrist and right (R) MCPJ 1, AUCs (0.813 to 0.897) for PD score > 1; L wrist and R MCPJs 1 and 3, AUCs (0.808 to 0.947) for GS score > 1. For CTCA (Table 1), 6 joint sites had ≥ 1 predictive parameter for either PD score > 1 and/or GS score > 1 as follows: BL wrists, AUCs (0.726 to 0.899) for PD score > 1; BL wrists, MCPJs 2 and 3, AUCs (0.739 to 0.931) for GS score > 1.Table 1.Identifying joints with ultrasound PD score >1 & GS score >1Thermal Imaging aloneCTCAJointUScriterionParameter (AUC ≥ 0.7& P <0.05)AUC(95% CI)Cut-offJointUScriterionParameter (AUC ≥ 0.7& P <0.05)AUC (95% CI)Cut-offLRLRLPD score >1Adjusted Tmax**0.841 (0.691, 0.992)4.7L & RPD score >1CTCA-MAX**0.899 (0.797, 1)**0.776 (0.578, .973)9.47.3WristAdjusted Tmin**0.813 (0.669, 0.958)2.85WristCTCA-MIN**0.861 (0.735, 0.987)*0.7265.74.45(0.526, 0.926)Adjusted Tavg**0.849 (0.714, 0.985)3.9CTCA-AVG**0.889 (0.781, 0.997)*0.7617.35.95(0.563, 0.959)GS score >1Adjusted Tmax**0.827 (0.687, 0.966)4.7GS score >1CTCA-MAX**0.918 (0.833, 1)**0.81387.3(0.632, 0.994)Adjusted Tmin**0.808 (0.67, 0.947)2.85CTCA-MIN**0.873 (0.761, 0.986)**0.7664.44.45(0.581, 0.951)Adjusted Tavg**0.837 (0.707, 0.967)3.9CTCA-AVG**0.913**0.8025.55.95(0.824, 1)(0.62, 0.985)RPD score >1Adjusted Tmax*0.897 (0.726, 1)5.7L & RGS score >1CTCA-MAX-*0.758-9.8(0.494, 1)MCPJ 1MCPJ 2GS score >1Adjusted Tmax*0.936 (0.813, 1)7.2CTCA-MIN*0.902*0.7392.753.9(0.775, 1)(0.443, 1)Adjusted Tmin*0.932 (0.793, 1)3.95CTCA-AVG*0.931**0.7634.75.5(0.835, 1)(0.474, 1)Adjusted Tavg*0.947 (0.868, 1)4.9L & RGS score >1CTCA-MAX*0.914*0.8736.3512.2(0.735, 1)(0.617, 1)RGS score >1Adjusted Tmax*0.922 (0.76, 1)4.6MCPJ 3CTCA-MIN-*0.902-3.15(0.75, 1)MCPJ 3CTCA-AVG-*0.902-4.1(0.728, 1)Corresponding P-value: statistically significance at *P <0.05, **P<0.01.ConclusionA novel CTCA approach helps discriminate the severity of US detected joint inflammation in RA at more joint sites when compared to TI alone; this includes the commonly affected BL wrists, MCPJs 2 and 3. Further validation work in a larger RA cohort will be required.Disclosure of InterestsNone declared
Collapse
|
27
|
Li R, Huang C, Hong C, Wang J, Li Q, Hu C, Cui H, Dong Z, Zhu H, Liu L, Xiao L. [Impact of nonsteroidal anti-inflammatory drugs on efficacy of anti-PD-1 therapy for primary liver cancer]. Nan Fang Yi Ke Da Xue Xue Bao 2022; 42:698-704. [PMID: 35673913 DOI: 10.12122/j.issn.1673-4254.2022.05.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To assess the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on clinical outcomes of patients receiving anti-PD-1 immunotherapy for hepatocellular carcinoma. METHODS We conducted a retrospective study among 215 patients with primary liver cancer receiving immunotherapy between June, 2018 and October, 2020. The patients with balanced baseline characteristics were selected based on propensity matching scores, and among them 33 patients who used NSAIDs were matched at the ratio of 1∶3 with 78 patients who did not use NSAIDs. We compared the overall survival (OS), progression-free survival (PFS), and disease control rate (DCR) between the two groups. RESULTS There was no significant difference in OS between the patients using NSAIDs (29.7%) and those who did not use NSAIDs (70.2%). Univariate and multivariate analyses did not show an a correlation of NSAIDs use with DCR (univariate analysis: OR=0.602, 95% CI: 0.299-1.213, P=0.156; multivariate analysis: OR=0.693, 95% CI: 0.330-1.458, P=0.334), PFS (univariate analysis: HR=1.230, 95% CI: 0.789-1.916, P=0.361; multivariate analysis: HR=1.151, 95% CI: 0.732-1.810, P=9.544), or OS (univariate analysis: HR=0.552, 95% CI: 0.208-1.463, P=0.232; multivariate analysis: HR=1.085, 95% CI: 0.685-1.717, P=0.729). CONCLUSION Our results show no favorable effect of NSAIDs on the efficacy of immunotherapy in patients with advanced primary liver cancer, but this finding still needs to be verified by future prospective studies of large cohorts.
Collapse
Affiliation(s)
- R Li
- Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.,Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - C Huang
- Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.,Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - C Hong
- Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.,Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - J Wang
- Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - Q Li
- Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - C Hu
- Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.,Department of Infectious Diseases, Guangzhou First People's Hospital, Guangzhou 510180, China
| | - H Cui
- Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - Z Dong
- Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - H Zhu
- Department of Oncology, First Affiliated Hospital of University of South China, Hengyang 421001, China
| | - L Liu
- Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.,Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - L Xiao
- Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.,Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| |
Collapse
|
28
|
Wang P, Yin B, Zhang Z, Mao S, Bao W, Lian W, Fan Y, Hong C, Su Y, Jia C. Foamy macrophages potentially inhibit tuberculous wound healing by inhibiting the TLRs/NF-κB signalling pathway. Wound Repair Regen 2022; 30:376-396. [PMID: 35384137 DOI: 10.1111/wrr.13006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Revised: 01/26/2022] [Accepted: 03/20/2022] [Indexed: 11/29/2022]
Abstract
To characterise the distribution, classification, and quantity of foamy macrophages (FMs) in tuberculous wound tissue and the relationship between FM and delayed healing of tuberculous wounds. Morphological studies were performed to explore the distribution of FM and Mycobacterium tuberculosis (Mtb) in tuberculous wounds, with acute and chronic wounds included for comparison. Phorbol-12-myristate-13-acetate stimulation-differentiated THP-1 cells were treated with Mtb to induce their differentiation into FM with oxidised low-density lipoprotein treatment serving as a control. Relative cytokine levels were determined by quantitative PCR and Western blotting. Varied co-culture combinations of Mtb, THP-1, FM, and fibroblasts were performed, and proliferation, migration, ability to contract collagen gel, and protein levels of the chemokines in the supernatants of the fibroblasts were assessed. The differentially expressed genes in human skin fibroblasts (HSFs) after co-culture with or without FM were identified using microarray. Many FM were found in the tissues of tuberculous wounds. The FM that did not engulf Mtb (NM-FM) were mainly distributed in tissues surrounding tuberculous wounds, whereas the FM that engulfed Mtb (M-FM) were dominantly located within granulomatous tissues. Co-culture experiments showed that, with the Mtb co-culture, the portions of NM-FM in the total FM grew over time. The migration, proliferation, chemokine secretion, and the ability of fibroblasts to contract collagen gel were inhibited when co-cultured with Mtb, FM, or a combination of the two. Further investigation showed that the TLRs/NF-κB signalling pathway is involved in fibroblast function under the stimulation of FM. TLRs and NF-κB agonists could reverse the phenotypic changes in HSFs after co-culture with FM. The tuberculous wound microenvironment composed of Mtb and FM may affect wound healing by inhibiting the functions of fibroblasts. FM potentially inhibit fibroblasts' function by inhibiting the TLRs/NF-κB signalling pathway in tuberculous wounds.
Collapse
Affiliation(s)
- Peng Wang
- Department of Burns and Plastic & Wound Repair Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| | - Bin Yin
- Department of Burns and Plastic & Wound Repair Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| | - Zexin Zhang
- Department of Burns and Plastic & Wound Repair Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| | - Shuting Mao
- Department of Burns and Plastic & Wound Repair Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| | - Wu Bao
- Department of Burns and Plastic & Wound Repair Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| | - Wenqin Lian
- Department of Burns and Plastic & Wound Repair Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| | - Yueying Fan
- Department of Burns and Plastic & Wound Repair Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| | - Chao Hong
- Xiamen Center for Disease Control and Prevention, Xiamen, China
| | - Yingjun Su
- Department of Burns and Plastic Surgery, Plastic Surgery Hospital of Xi'an International Medical Center, Xi'an, China
| | - Chiyu Jia
- Department of Burns and Plastic & Wound Repair Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
| |
Collapse
|
29
|
Hong C, Ren J. Research on the Implementation of Public Physical Education under the Network Environment. Appl Bionics Biomech 2022; 2022:6391614. [PMID: 35386211 PMCID: PMC8977289 DOI: 10.1155/2022/6391614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 03/07/2022] [Accepted: 03/10/2022] [Indexed: 11/17/2022] Open
Abstract
In order to improve the physical quality of contemporary students, the public physical education teaching of big data technology is introduced to enrich the interest of physical education classroom and improve the enthusiasm of students through targeted teaching means. In this paper, through the big data of students' physical performance and students' physical quality, an expert system for physical education curriculum recommendation is established to teach students according to their aptitude and increase the intelligent management of the classroom. The SPSS simulation experiment is carried out according to the big data of students' physical performance and physical quality. Finally, it is concluded that the system can improve students' interest in physical exercise, increase the vividness of the classroom, and improve students' physical quality.
Collapse
Affiliation(s)
- Chao Hong
- School of Department of PE, Dankook University, Yongin-si, Republic of Korea
| | - Jie Ren
- Sports Department, Guilin Medical University, Guilin, China
| |
Collapse
|
30
|
Choo J, Yap J, Ismail AIDILA, Lim CL, Sumathy P, Ruan W, Sewa DW, Phua GC, Hong C, Low AHL, Lim ST, Tan JL. Intravenous epoprostenol therapy in the treatment of pulmonary arterial hypertension: the Singapore experience. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehab849.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Pulmonary arterial hypertension (PAH) is a progressive disease with significant morbidity and mortality. While intravenous (IV) Epoprostenol, a prostacyclin analogue, has been shown to improve exercise tolerance, symptoms, hemodynamics and survival, there are challenges with initiation and maintenance of this IV therapy.
Purpose
We aim to describe our local experience of the use of IV Epoprostenol in the treatment of PAH patients in Singapore, highlighting various issues and challenges.
Methods
From 2016, patients at a tertiary cardiac institution diagnosed with Group 1 PAH and remaining in intermediate to high risk class with progressive symptoms (despite being on maximum tolerable doses of PhosphoDiEsterase-5 inhibitors and Endothelin-1 receptor antagonists) were assessed and counselled for initiation of Epoprostenol therapy. With a fixed set of local protocols, comprehensive assessment and support of a multi-disciplinary team including physicians, specialist nurses and pharmacists, suitable patients were started on this treatment.
Results
A total of 12 patients (11 female, mean age 42.8 +/- 11.0 years) were included. The average New York Heart Association class of the patients initiated on Epoprostenol was II-III. The pulmonary artery pressures and pulmonary vascular resistance on right heart catheterization prior to initiation was 52.5 (IQR 47.0-54.0) mmHg and 12.6 (IQR 10.0-14.2) Woods respectively. The duration from diagnosis to time of initiating Epoprostenol was 89 (IQR 62-140) months. Epoprostenol was generally well tolerated. The most common side effect experienced was diarrhea (5/12 patients) followed by headache and musculoskeletal complains (3/12 patients each). Of the 12 patients, 6 passed away after 12 (IQR 10-16) months of Epoprostenol therapy. Of the remaining 6, PAH was diagnosed 110 (IQR 104-136) months ago and Epoprostenol therapy has been continued for 17 (IQR 14-27) months. Of those who survived, right ventricle size and PA pressures on echocardiography remained relatively stable as compared to those who passed on. 2 patients had line related infections requiring a line change 1 and 2 times respectively.
Conclusion
While not without its challenges, the establishment of concrete protocols with the support of a multidisciplinary team allows for the introduction of IV Epoprostenol as an additional potential line of effective therapy for PAH patients in Singapore.
Collapse
Affiliation(s)
- J Choo
- National Heart Centre Singapore, Singapore, Singapore
| | - J Yap
- National Heart Centre Singapore, Singapore, Singapore
| | - AIDILA Ismail
- National Heart Centre Singapore, Singapore, Singapore
| | - C L Lim
- National Heart Centre Singapore, Singapore, Singapore
| | - P Sumathy
- National Heart Centre Singapore, Singapore, Singapore
| | - W Ruan
- National Heart Centre Singapore, Singapore, Singapore
| | - D W Sewa
- Singapore General Hospital, Singapore, Singapore
| | - G C Phua
- Singapore General Hospital, Singapore, Singapore
| | - C Hong
- Singapore General Hospital, Singapore, Singapore
| | - A H L Low
- Singapore General Hospital, Singapore, Singapore
| | - S T Lim
- National Heart Centre Singapore, Singapore, Singapore
| | - J L Tan
- National Heart Centre Singapore, Singapore, Singapore
| |
Collapse
|
31
|
Zhou YP, Wei YP, Yang YJ, Peng FH, Wu BX, Hong C, Tong Q, Cui XP, Zhang GC, Cao YS, Wang DL, Xu XQ, Jiang X, Jing ZC. Refined balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: a prospective multicenter registry. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehab849.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Foundation. Main funding source(s): the National Key Research and Development Program of China
Background Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening disease with a poor prognosis if left untreated. Pulmonary endarterectomy is the standard treatment for CTEPH, but around 40% of CTEPH patients are non-eligible for surgery.
Purpose To investigate the efficacy and safety of refined balloon pulmonary angioplasty (BPA) for inoperable CTEPH in a prospective multicenter registry from China.
Methods We conducted a prospective multicenter cohort study using the data from National Rare Disease Registry System of China. Total 140 consecutive patients with inoperable CTEPH who completed BPA between Jan 2016 and Dec 2020 were enrolled. The key efficacy outcomes were changes from baseline to re-evaluation in mean pulmonary arterial pressure, pulmonary vascular resistance, and six-minute walking distance. The safety outcomes were procedure-related complications. The survival outcome was all-cause mortality.
Results Among the 140 patients who completed BPA, the mean age at diagnosis was 58 ± 14 years and 60.0% were female. At re-evaluation, the least-squares mean change from baseline was -18.3 mm Hg (95% confidence interval [CI], -19.9 to -16.6, P < 0.001) in mean pulmonary arterial pressure, -5.3 Wood U (95% CI, -5.9 to -4.6, P < 0.001) in pulmonary vascular resistance, and 87 meters (95% CI, 74 to 101, P < 0.001) in six-minute walking distance. BPA procedure-related complications occurred in 109 of 650 BPA sessions (16.8%), but severe complications requiring noninvasive positive pressure ventilation only occurred in 4 (0.6%) BPA sessions. During a mean follow-up time of 32 ± 14 months, 4 patients died, including 2 peri-procedural deaths, contributing to the survival rates of 97.8% (95% CI, 93.4 to 99.3) at 1 year and 96.9% (95% CI, 91.9 to 98.8) at 3 and 5 years.
Conclusion Refined BPA appears to be an effective therapeutic option for inoperable CTEPH patients with acceptable safety profiles. Abstract Figure. Images of BPA Efficacy in a Patient Abstract Figure. Efficacy outcomes of BPA
Collapse
Affiliation(s)
- Y-P Zhou
- Peking Union Medical College Hospital, Beijing, China
| | - Y-P Wei
- Peking Union Medical College Hospital, Beijing, China
| | - Y-J Yang
- Peking Union Medical College Hospital, Beijing, China
| | - F-H Peng
- FuWai Hospital, Chinese Academy Medical Sciences, Beijing, China
| | - B-X Wu
- The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | - C Hong
- Guangzhou Medical University, Guangzhou, China
| | - Q Tong
- First Hospital of Jilin University, Changchun, China
| | - X-P Cui
- Shandong University Qilu Hospital, Jinan, China
| | - G-C Zhang
- Wuhan Asia Heart Hospital, Wuhan, China
| | - Y-S Cao
- Gansu Provincial Hospital, Lanzhou, China
| | - D-L Wang
- Liverpool School of Tropical Medicine, Liverpool, United Kingdom of Great Britain & Northern Ireland
| | - X-Q Xu
- Peking Union Medical College Hospital, Beijing, China
| | - X Jiang
- Peking Union Medical College Hospital, Beijing, China
| | - Z-C Jing
- Peking Union Medical College Hospital, Beijing, China
| |
Collapse
|
32
|
Hong C, Yu S, Liu Z, Zhang Y. Rh-Catalyzed Coupling of Acrylic/Benzoic Acids with α-Diazocarbonyl Compounds: An Alternative Route for α-Pyrones and Isocoumarins. Org Lett 2022; 24:815-820. [PMID: 35019648 DOI: 10.1021/acs.orglett.1c03992] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A coupling of acrylic acids/benzoic acids with α-diazocarbonyl compounds has been realized by a combined catalytic system of rhodium catalyst and Zn(OAc)2 additive. The presence of Zn(OAc)2 obviously accelerates the C(sp2)-H activation and destructed the formation of carboxylic ester that is formed via a nucleophilic O-H insertion to metal carbenoid. The procedure featured mild reaction conditions and broad substrate scope, providing a straightforward approach to the synthesis of α-pyrones and isocoumarins without the transformation of carboxylic acids to the corresponding amides.
Collapse
Affiliation(s)
- Chao Hong
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Shuling Yu
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Zhanxiang Liu
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Yuhong Zhang
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China.,State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, China
| |
Collapse
|
33
|
Yao L, Hong C, Dashtifard H, Esmaeili H. Selective Removal of Sodium Ions from Aqueous Media Using Effective Adsorbents: Optimization by RSM and Genetic Algorithm. Acta Chim Slov 2021; 68:791-803. [PMID: 34918768 DOI: 10.17344/acsi.2021.6762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 09/09/2021] [Accepted: 09/13/2021] [Indexed: 11/19/2022] Open
Abstract
This study aimed to determine the best adsorbent among Moringa oleifera-derived activated carbon (AC), eggshell-derived CaO nanoparticles and CaO/Fe3O4 for sodium (Na+) removal from aqueous media. In the first step, the appropriate adsorbent for sodium adsorption was determined among the three adsorbents, which the results showed that the AC had the highest sorption efficiency. Then, response surface methodology (RSM) was used to evaluate the impact of different factors on the Na+ ion sorption efficiency using the AC. The highest removal efficiency was obtained to be 95.91% at optimum conditions such as pH of 11, contact time of 45 min, temperature of 25 °C, sodium ion concentration of 900 mg/L, and adsorbent dosage of 5 g/L. Also, the best conditions using the genetic algorithm was obtained at contact time of 94.97 min, adsorbent dosage of 3.52 g/L, Na+ ion concentration of 939.92 mg/L and pH value of 10.92. Moreover, the maximum sorption capacity using the Langmuir model was obtained to be 249.67 mg/g, which was a significant value. Besides, the equilibrium and kinetic studies indicated that the experimental data of sodium adsorption process were fitted well with the Langmuir isotherm model and the pseudo-second-order kinetic model, respectively. Furthermore, the thermodynamic study indicated that the sorption process was endothermic. Generally, among the three adsorbents used, activated carbon with a high removal efficiency and significant sorption capacity can be considered as a promising adsorbent for the removal of sodium from wastewater on an industrial scale.
Collapse
Affiliation(s)
- Lei Yao
- College of Civil and Architecture Engineering, Chuzhou University, Chuzhou 239000, Anhui, China.
| | | | | | | |
Collapse
|
34
|
Abstract
A carboxyl-assisted C-H functionalization of acrylic acids with formaldehyde to give butenolides is described. It is the first time that the addition of an inert vinylic C-H bond to formaldehyde has been achieved via cobalt-catalyzed C-H activation. The unique reactivity of the cobalt species was observed when compared with related Rh or Ir catalysts. γ-Hydroxymethylated butenolides were produced by the treatment of Na2CO3 after the catalytic reaction in one pot.
Collapse
Affiliation(s)
- Shuling Yu
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Chao Hong
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Zhanxiang Liu
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Yuhong Zhang
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China.,State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, China
| |
Collapse
|
35
|
Zhu YJ, Jiang X, Peng FH, Wang L, Ma W, Cao YS, Pan X, Zhang GC, Zhang F, Fan FL, Wu BX, Huang W, Yang ZW, Hong C, Jing ZC. Clinical features and survival in pulmonary Takayasu's arteritis associated pulmonary hypertension: a national registry study. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The clinical features and long-term outcomes of patients with pulmonary Takayasu's arteritis associated pulmonary hypertension (PTA-PH) have not been well studied.
Purpose
To assess the clinical characteristics and long-term survival outcome in patients with PTA-PH.
Methods
We conducted a multi-center cohort study using the clinical, functional, and hemodynamic data from the National Rare Diseases Registry System of China. Patients with Takayasu's arteritis and pulmonary artery involvement, who fulfilled the 1990 American College of Rheumatology and/or modified Ishikawa criteria, from 13 referral centers of China, were included. The diagnosis of pulmonary hypertension (PH) was confirmed by right heart catheterization findings. The primary outcome was time from diagnosis of PTA-PH to the occurrence of all-cause death.
Results
Between Jan. 2007 and Jan. 2019, a total of 140 patients with PTA-PH were included, with a mean age of 41.4±14.3 years at diagnosis, and a female predominance (81%). The most common symptoms were exertional dyspnea (91%) and hemoptysis (36%). The majority of patients (87%) exhibited bilateral pulmonary artery involvement. Pulmonary lobar artery was the most frequently affected vessel (100%), followed by segmental artery (82%) and left/right pulmonary artery trunk (49%). Severely compromised hemodynamic profiles were identified in these patients, indicating by elevated mean pulmonary artery pressure (48, interquartile range [IQR] 38–59 mm Hg) and pulmonary vascular resistance (9.4, IQR 5.7–13.3 Wood U). The overall 1-year, 3-year, and 5-year survival rates in PTA-PH were 94.0%, 83.2%, and 77.2%, respectively (Figure). Predictors associated with increased risk of all-cause death were the presence of syncope (hazard ratio [HR]: 4.88; 95% CI: 1.62–14.74; p=0.005), N-terminal pro-B type natriuretic peptide level (HR: 1.04; 95% CI: 1.02–1.06; p<0.001), and right atrial pressure (HR: 1.07; 95% CI: 1.02–1.73; p=0.009).
Conclusions
In this national registry study, the reported clinical features and long-term prognosis of patients with PTA-PH are novel findings. These findings may provide new insights on this specific pulmonary hypertension entity.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): The National Key Research and Development Program of China Kaplan-Meier plot for survival rate
Collapse
Affiliation(s)
- Y.-J Zhu
- Peking Union Medical College Hospital, Beijing, China
| | - X Jiang
- Peking Union Medical College Hospital, Beijing, China
| | - F.-H Peng
- FuWai Hospital, Peking Union Medical College & Chinese Academy Medical Sciences, beijing, China
| | - L Wang
- Shanghai Pulmonary Hospital of Tongji University School of Medicine, Shanghai, China
| | - W Ma
- Peking University First Hospital, Beijing, China
| | - Y.-S Cao
- Gansu Provincial Hospital, Lanzhou, China
| | - X Pan
- Shanghai Chest Hospital, Shanghai, China
| | | | - F Zhang
- General Hospital of Xinjiang Military Region, Urumqi, China
| | - F.-L Fan
- the First Affiliated Hospital of Xi an Jiaotong University, Xi'an, China
| | - B.-X Wu
- The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | - W Huang
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Z.-W Yang
- Tianjin Medical University General Hospital, Tianjin, China
| | - C Hong
- No.1 Hospital of Guangzhou Medical College, Guangzhou, China
| | - Z.-C Jing
- Peking Union Medical College Hospital, Beijing, China
| |
Collapse
|
36
|
Hong C, Lu H, Jin R, Huang X, Chen M, Dai X, Gong F, Dong H, Wang H, Gao XM. Cytokine Cocktail Promotes Alveolar Macrophage Reconstitution and Functional Maturation in a Murine Model of Haploidentical Bone Marrow Transplantation. Front Immunol 2021; 12:719727. [PMID: 34621268 PMCID: PMC8490745 DOI: 10.3389/fimmu.2021.719727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2021] [Accepted: 09/02/2021] [Indexed: 11/23/2022] Open
Abstract
Infectious pneumonia is one of the most common complications after bone marrow transplantation (BMT), which is considered to be associated with poor reconstitution and functional maturation of alveolar macrophages (AMs) post-transplantation. Here, we present evidence showing that lack of IL-13-secreting group 2 innate lymphoid cells (ILC2s) in the lungs may underlay poor AM reconstitution in a mouse model of haploidentical BMT (haplo-BMT). Recombinant murine IL-13 was able to potentiate monocyte-derived AM differentiation in vitro. When intranasally administered, a cocktail of granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-13, and CCL2 not only promoted donor monocyte-derived AM reconstitution in haplo-BMT-recipient mice but also enhanced the innate immunity of the recipient animals against pulmonary bacterial infection. These results provide a useful clue for a clinical strategy to prevent pulmonary bacterial infection at the early stage of recipients post-BMT.
Collapse
Affiliation(s)
- Chao Hong
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Hongyun Lu
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Rong Jin
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Xiaohong Huang
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Ming Chen
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Xiaoqiu Dai
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Fangyuan Gong
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Hongliang Dong
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Hongmin Wang
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Xiao-Ming Gao
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| |
Collapse
|
37
|
Yu S, Hong C, Liu Z, Zhang Y. Synthesis of Cyclopentenones through Rhodium-Catalyzed C-H Annulation of Acrylic Acids with Formaldehyde and Malonates. Org Lett 2021; 23:5054-5059. [PMID: 34151579 DOI: 10.1021/acs.orglett.1c01569] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
An efficient rhodium-catalyzed protocol for the synthesis of cyclopentenones based on a three-component reaction of acrylic acids, formaldehyde, and malonates via vinylic C-H activation is reported. Exploratory studies showed that 5-alkylation of as-prepared cyclopentenones could be realized smoothly by the treatment of a variety of alkyl halides with a Na2CO3/MeOH solution. Excess formaldehyde and malonate led to a multicomponent reaction that afforded the multisubstituted cyclopentenones through a Michael addition.
Collapse
Affiliation(s)
- Shuling Yu
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Chao Hong
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Zhanxiang Liu
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Yuhong Zhang
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China.,State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, China
| |
Collapse
|
38
|
Tan YK, Hong C, LI H, Allen JC, Thumboo J. AB0787 RECEIVER OPERATING CHARACTERISTIC ANALYSIS OF JOINT INFLAMMATION IN RELATION TO DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS ASSESSED USING A NOVEL COMBINED THERMAL AND ULTRASOUND IMAGING. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.514] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:A novel combined thermal and ultrasound (CTUS) imaging approach in rheumatoid arthritis (RA) was recently shown to be superior to either imaging modality alone in terms of correlation with the 28-joint disease activity score (DAS28).Objectives:To determine the performance of CTUS imaging in identifying RA patients with at least moderate disease activity (DAS28 > 3.2).Methods:Bilateral hand (22 joints) thermal and ultrasound (US) imaging was performed. Thermal imaging provides the surface temperature readings at the joints with MAX, AVG and MIN derived per patient by summing the temperature differences with a control temperature, for the respective maximum (Tmax), average (Tavg) and minimum (Tmin) temperatures at each joint. US imaging assesses joint inflammation by summing up the power Doppler (PD) and grey-scale (GS) joint inflammation scores (graded 0-3 at each joint recess) at each joint to obtain the respective total PD and total GS scores per patient. CTUS imaging utilizes data from both thermal and US imaging to derive the MAX (PD), AVG (PD) and MIN (PD) by multiplying MAX, AVG and MIN by a factor of 2 when a patient’s Total PD > median score, which otherwise remained the same as the MAX, AVG and MIN. The results of the imaging parameters were compared between patients with DAS28 ≤ 3.2 and those with DAS28 > 3.2. Sensitivity (Sn), specificity (Sp) and receiver operating characteristic (ROC) curve analysis was performed to determine if the use of CTUS imaging can help identify patients with DAS28 > 3.2.Results:In this cross-sectional study, 814 joints from 37 RA patients (75.7% female; 75.7% Chinese; baseline mean disease duration, 30.9 months; baseline mean DAS28, 4.43) were imaged. The mean (SD) values for the CTUS—but not single modality—imaging parameters (Table 1) were all significantly greater among patients with DAS28 > 3.2 versus those with DAS28 ≤ 3.2 (P-values were all <0.01). Based on cut-off levels of (a) MAX (PD) ≥ 94.5, (b) MIN (PD) ≥ 42.3 and (c) AVG (PD) ≥ 64.6 in identifying patients with DAS28 > 3.2, the respective area under the ROC curves (AUCs) (95%CIs) were (a) 0.731 (0.541, 0.921) with Sn = 58.1%; Sp = 100.0%; negative predictive value (NPV) = 31.6%; positive predictive value (PPV) = 100.0%; accuracy = 64.9%, (b) 0.758 (0.591, 0.925) with Sn = 61.3%; Sp = 100.0%; NPV = 33.3%; PPV = 100.0%; accuracy = 67.6% and (c) 0.763 (0.596, 0.931) with Sn = 61.3%; Sp = 100.0%; NPV = 33.3%; PPV = 100.0%; accuracy = 67.6%.Conclusion:The severity of joint inflammation as detected by CTUS—but not single modality—imaging parameters were significantly greater among patients with DAS28 > 3.2 versus those with DAS28 ≤ 3.2. For the first time ever, by applying ROC analysis, this has helped to determine cut-off MAX (PD), MIN (PD) and AVG (PD) levels for identifying patients with DAS28 > 3.2; the usefulness of these cut-off levels will require further validation in independent RA cohorts.Table 1.Comparison of imaging parameters between patient groups.Imaging ParameterDAS28 Mean (95% CI)Difference (95% CI)P-valueDAS28 ≤ 3.2DAS28 > 3.2MAX (PD)75.25 (58.8, 91.7)119.5 (101.12, 137.87)-44.25 (-70.49, -18.01)0.0022**MIN (PD)33.72 (25.82, 41.61)57.51 (47.63, 67.39)-23.79 (-37.13, -10.45)0.0012**AVG (PD)50.72 (39.45, 61.98)85.39 (71.89, 98.88)-34.67 (-53.27, -16.07)0.0008***MAX67.38 (50.75, 84.02)82.23 (74.71, 89.75)-14.85 (-34.11, 4.42)0.1268MIN30.27 (22.06, 38.47)40.02 (35.02, 45.03)-9.75 (-22.18, 2.66)0.1198AVG45.45 (33.94, 56.96)59.11 (52.99, 65.23)-13.66 (-29.04, 1.72)0.0801Total PD2.83 (-0.23, 5.9)3.65 (2.71, 4.58)-0.82 (-3.39, 1.77)0.5269Total GS6.67 (1.31, 12.02)6.58 (4.12, 9.04)0.09 (-6.21, 6.38)0.9780Statistically significant: **P<0.01, ***P<0.001.Disclosure of Interests:None declared
Collapse
|
39
|
Lu Y, Hong C, Chang K, Lee C. 618 Glucose transporter 1 enhances glycolysis, oxidative stress, and fibroblast proliferation in keloid. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
40
|
Pu J, Yu Q, Yin Z, Zhang Y, Li X, Yin Q, Chen H, Long R, Zhao Z, Mou T, Zhao H, Feng S, Xie Z, Wang L, He Z, Liao Y, Fan S, Jiang R, Wang J, Zhang L, Li J, Zheng H, Cui P, Jiang G, Guo L, Xu M, Yang H, Lu S, Wang X, Gao Y, Xu X, Cai L, Zhou J, Yu L, Chen Z, Hong C, Du D, Zhao H, Li Y, Ma K, Ma Y, Liu D, Yao S, Li C, Che Y, Liu L, Li Q. The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial. Vaccine 2021; 39:2746-2754. [PMID: 33875266 PMCID: PMC8040531 DOI: 10.1016/j.vaccine.2021.04.006] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Revised: 03/10/2021] [Accepted: 04/06/2021] [Indexed: 01/15/2023]
Abstract
Background This study examined the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine. Method In a phase I randomized, double-blinded, placebo-controlled trial involving 192 healthy adults 18–59 years old, two injections of three doses (50 EU, 100 EU, 150 EU) of an inactivated SARS-CoV-2 vaccine or placebo were administered intramuscularly at a 2- or 4-week interval. The safety and immunogenicity of the vaccine were evaluated. Results Vaccination was completed in 191 subjects. Forty-four adverse reactions occurred within 28 days, most commonly mild pain and redness at the injection site or slight fatigue. At days 14 and 28, the seroconversion rates were 87.5% and 79.2% (50 EU), 100% and 95.8% (100 EU), and 95.8% and 87.5% (150 EU), respectively, with geometric mean titers (GMTs) of 18.1 and 10.6, 54.5 and 15.4, and 37.1 and 18.5, respectively, for the schedules with 2-week and 4-week intervals. Seroconversion was associated with synchronous upregulation of antibodies against the S protein, N protein and virion and a cytotoxic T lymphocyte (CTL) response. No cytokines and immune cells related to immunopathology were observed. Transcriptome analysis revealed the genetic diversity of immune responses induced by the vaccine. Interpretation In a population aged 18–59 years in this trial, this inactivated SARS-CoV-2 vaccine was safe and immunogenic. Trial registration: CTR20200943 and NCT04412538.
Collapse
Affiliation(s)
- Jing Pu
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Qin Yu
- National Drug Clinical Trial Institution of West China Second Hospital, Sichuan University, Chengdu 610041, China
| | - Zhifang Yin
- National Institute of Food and Drug Control, Beijing 100050, China
| | - Ying Zhang
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Xueqi Li
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Qiongzhou Yin
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Hongbo Chen
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Runxiang Long
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Zhimei Zhao
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Tangwei Mou
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Heng Zhao
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Shiyin Feng
- National Drug Clinical Trial Institution of West China Second Hospital, Sichuan University, Chengdu 610041, China
| | - Zhongping Xie
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Lichun Wang
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Zhanlong He
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Yun Liao
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Shengtao Fan
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Ruiju Jiang
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Jianfeng Wang
- National Institute of Food and Drug Control, Beijing 100050, China
| | - Lingli Zhang
- National Drug Clinical Trial Institution of West China Second Hospital, Sichuan University, Chengdu 610041, China
| | - Jing Li
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Huiwen Zheng
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Pingfang Cui
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Guorun Jiang
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Lei Guo
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Mingjue Xu
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Huijuan Yang
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Shan Lu
- Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
| | - Xuanyi Wang
- The Institutes of Biomedical Science, Shanghai Medical College, Fudan University, Shanghai 200032, China
| | - Yang Gao
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Xingli Xu
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Linrui Cai
- National Drug Clinical Trial Institution of West China Second Hospital, Sichuan University, Chengdu 610041, China
| | - Jian Zhou
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Li Yu
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Zhuo Chen
- National Drug Clinical Trial Institution of West China Second Hospital, Sichuan University, Chengdu 610041, China
| | - Chao Hong
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Dan Du
- National Drug Clinical Trial Institution of West China Second Hospital, Sichuan University, Chengdu 610041, China
| | - Hongling Zhao
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Yan Li
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Kaili Ma
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Yunfei Ma
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Donglan Liu
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Shibao Yao
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China
| | - Changgui Li
- National Institute of Food and Drug Control, Beijing 100050, China.
| | - Yanchun Che
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China.
| | - Longding Liu
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China.
| | - Qihan Li
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China.
| |
Collapse
|
41
|
Hong C, Jin R, Dai X, Gao X. Functional Contributions of Antigen Presenting Cells in Chronic Graft-Versus-Host Disease. Front Immunol 2021; 12:614183. [PMID: 33717098 PMCID: PMC7943746 DOI: 10.3389/fimmu.2021.614183] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Accepted: 01/11/2021] [Indexed: 12/27/2022] Open
Abstract
Chronic graft-versus-host disease (cGVHD) is one of the most common reasons of late non-relapse morbidity and mortality of patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). While acute GVHD is considered driven by a pathogenic T cell dominant mechanism, the pathogenesis of cGVHD is much complicated and involves participation of a variety of immune cells other than pathogenic T cells. Existing studies have revealed that antigen presenting cells (APCs) play crucial roles in the pathophysiology of cGVHD. APCs could not only present auto- and alloantigens to prime and activate pathogenic T cells, but also directly mediate the pathogenesis of cGVHD via multiple mechanisms including infiltration into tissues/organs, production of inflammatory cytokines as well as auto- and alloantibodies. The studies of this field have led to several therapies targeting different APCs with promising results. This review will focus on the important roles of APCs and their contributions in the pathophysiology of cGVHD after allo-HSCT.
Collapse
Affiliation(s)
- Chao Hong
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Rong Jin
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Xiaoqiu Dai
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Xiaoming Gao
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| |
Collapse
|
42
|
Zhu Y, Liang J, Gao C, Wang A, Xia J, Hong C, Zhong Z, Zuo Z, Kim J, Ren H, Li S, Wang Q, Zhang F, Wang J. Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy. J Control Release 2021; 330:641-657. [DOI: 10.1016/j.jconrel.2020.12.036] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Revised: 12/12/2020] [Accepted: 12/20/2020] [Indexed: 12/12/2022]
|
43
|
|
44
|
Hong C, Yu S, Liu Z, Zhang Y. Rhodium(iii)-catalyzed annulation of enamides with sulfoxonium ylides toward isoquinolines. RSC Adv 2021; 11:11490-11494. [PMID: 35423634 PMCID: PMC8698508 DOI: 10.1039/d1ra01063h] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Accepted: 03/12/2021] [Indexed: 12/17/2022] Open
Abstract
An efficient rhodium(iii)-catalyzed C–H activation followed by intermolecular annulation between enamides and sulfoxonium ylides has been developed. The transformation proceeds smoothly with a broad range of substrates, affording a series of isoquinoline derivatives in moderate to good yields under additive-free conditions. An efficient rhodium(iii)-catalyzed C–H activation followed by intermolecular annulation between enamides and sulfoxonium ylides has been developed.![]()
Collapse
Affiliation(s)
- Chao Hong
- Department of Chemistry
- Zhejiang University
- Hangzhou 310027
- People's Republic of China
| | - Shuling Yu
- Department of Chemistry
- Zhejiang University
- Hangzhou 310027
- People's Republic of China
| | - Zhanxiang Liu
- Department of Chemistry
- Zhejiang University
- Hangzhou 310027
- People's Republic of China
| | - Yuhong Zhang
- Department of Chemistry
- Zhejiang University
- Hangzhou 310027
- People's Republic of China
- State Key Laboratory of Applied Organic Chemistry
| |
Collapse
|
45
|
Lv N, Yu S, Hong C, Han DM, Zhang Y. Selectively Oxidative C(sp2)–H/C(sp3)–H Cross-Coupling of Benzamides with Amides by Nickel Catalysis. Org Lett 2020; 22:9308-9312. [DOI: 10.1021/acs.orglett.0c03535] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Ningning Lv
- College of Chemistry & Materials Engineering, Wenzhou University, Wenzhou 325035, China
| | - Shuling Yu
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Chao Hong
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - De-Man Han
- Department of Chemistry, Taizhou University, Jiaojiang 318000, China
| | - Yuhong Zhang
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| |
Collapse
|
46
|
Dong H, Yang Y, Gao C, Sun H, Wang H, Hong C, Wang J, Gong F, Gao X. Lactoferrin-containing immunocomplex mediates antitumor effects by resetting tumor-associated macrophages to M1 phenotype. J Immunother Cancer 2020; 8:jitc-2019-000339. [PMID: 32217759 PMCID: PMC7174070 DOI: 10.1136/jitc-2019-000339] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/01/2020] [Indexed: 12/30/2022] Open
Abstract
Background Tumor-associated macrophages (TAMs) resemble M2-polarized cells with potent immunosuppressive activity and play a pivotal role in tumor growth and progression. Converting TAMs to proinflammatory M1-like phenotype is thus an attractive strategy for antitumor immunotherapy. Methods A mouse IgG1 (kappa) monoclonal Ab, M-860, specific to human lactoferrin (LTF) was generated by using the traditional hybridoma cell fusion technology. TAMs were generated by culturing human and mouse CD14+ monocytes in tumor-conditioned media containing a cytokine cocktail containing recombinant interleukin-4 (IL-4), interleukin-10 (IL-10) and macrophage colony stimulating factor (M-CSF). TAMs after treatment with immunocomplex (IC) between human LTF and M860 (LTF-IC) were phenotypically and functionally characterized by flow cytometry (FACS), ELISA, Q-PCR and killing assays. The antitumor effects of LTF-IC were further analyzed using in vivo experiments employing tumor-bearing human FcγRIIa-transgenic mouse models. Results Through coligation of membrane-bound CD14 and FcγRIIa, LTF-IC rendered TAMs not only M2 to M1 conversion, evidenced by increased tumor necrosis factor α production, down-regulated M2-specific markers (CD206, arginase-1 and vascular endothelial growth factor) and upregulated M1-specific markers (CD86 and HLA-DR) expression, but also potent tumoricidal activity in vitro. LTF-IC administration conferred antitumor protective efficacy and prolonged animal survival in FcγRIIa-transgenic mice, accompanied by accumulation of M1-like macrophages as well as significantly reduced infiltration of immunosuppressive myeloid-derived suppressor cells and regulatory T cells in solid tumor tissues. Conclusions LTF-IC is a promising cancer therapeutic agent capable of converting TAMs into tumoricidal M1-like cells.
Collapse
Affiliation(s)
- Hongliang Dong
- Institute of Biology and Medical Sciences, School of Biology and Basic Medical Science, Soochow University, Suzhou, China
| | - Yueyao Yang
- Institute of Biology and Medical Sciences, School of Biology and Basic Medical Science, Soochow University, Suzhou, China
| | - Chenhui Gao
- Institute of Biology and Medical Sciences, School of Biology and Basic Medical Science, Soochow University, Suzhou, China
| | - Hehe Sun
- Institute of Biology and Medical Sciences, School of Biology and Basic Medical Science, Soochow University, Suzhou, China
| | - Hongmin Wang
- Institute of Biology and Medical Sciences, School of Biology and Basic Medical Science, Soochow University, Suzhou, China
| | - Chao Hong
- Institute of Biology and Medical Sciences, School of Biology and Basic Medical Science, Soochow University, Suzhou, China
| | - Jun Wang
- Institute of Biology and Medical Sciences, School of Biology and Basic Medical Science, Soochow University, Suzhou, China
| | - Fangyuan Gong
- Institute of Biology and Medical Sciences, School of Biology and Basic Medical Science, Soochow University, Suzhou, China
| | - Xiaoming Gao
- Institute of Biology and Medical Sciences, School of Biology and Basic Medical Science, Soochow University, Suzhou, China
| |
Collapse
|
47
|
Che Y, Liu X, Pu Y, Zhou M, Zhao Z, Jiang R, Yin Z, Xu M, Yin Q, Wang J, Pu J, Zhao H, Zhang Y, Wang L, Jiang Y, Lei J, Zheng Y, Liao Y, Long R, Yu L, Cui P, Yang H, Zhang Y, Li J, Chen W, He Z, Ma K, Hong C, Li D, Jiang G, Liu D, Xu X, Fan S, Cheng C, Zhao H, Yang J, Li Y, Zou Y, Zhu Y, Zhou Y, Guo Y, Yang T, Chen H, Xie Z, Li C, Li Q. Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults. Clin Infect Dis 2020; 73:e3949-e3955. [PMID: 33165503 PMCID: PMC7717222 DOI: 10.1093/cid/ciaa1703] [Citation(s) in RCA: 52] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Accepted: 11/06/2020] [Indexed: 11/18/2022] Open
Abstract
Background We evaluated an inactivated SARS-CoV-2 vaccine for immunogenicity and safety in adults aged 18-59 years. Methods In this randomized, double-blinded and controlled trial, healthy adults received a medium (MD) or a high dose (HD) of the vaccine at an interval of either 14 days or 28 days. Neutralizing antibody (NAb) and anti-S and anti-N antibodies were detected at different times, and adverse reactions were monitored for 28 days after full immunization. Results A total of 742 adults were enrolled in the immunogenicity and safety analysis. Among subjects in the 0, 14 procedure, the seroconversion rates of NAb in MD and HD groups were 89% and 96% with GMTs of 23 and 30, respectively, at day 14 and 92% and 96% with GMTs of 19 and 21, respectively at day 28 after immunization. Anti-S antibodies had GMTs of 1883 and 2370 in MD and 2295 and 2432 in HD group. Anti-N antibodies had GMTs of 387 and 434 in MD group and 342 and 380 in HD group. Among subjects in the 0, 28 procedure, seroconversion rates for NAb at both doses were both 95% with GMTs of 19 at day 28 after immunization. Anti-S antibodies had GMTs of 937 and 929 for MD and HD group, and anti-N antibodies had GMTs of 570 and 494 for MD and HD group, respectively. No serious adverse events were observed during the study period. Conclusion Adults vaccinated with inactivated SARS-CoV-2 vaccine had NAb as well as anti-S/N antibody, and had a low rate of adverse reactions. Clinical trials registration NCT04412538.
Collapse
Affiliation(s)
- Yanchun Che
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Xiaoqiang Liu
- Yunnan Center for Disease Control and Prevention, Kunming, China
| | - Yi Pu
- Gejiu Center for Disease Control and Prevention, Gejiu, China
| | - Meijian Zhou
- Mile Center for Disease Control and Prevention, Mile, China
| | - Zhimei Zhao
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Ruiju Jiang
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Zhifang Yin
- National Institute of Food and Drug Control, Beijing, China
| | - Mingjue Xu
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Qiongzhou Yin
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Jianfeng Wang
- National Institute of Food and Drug Control, Beijing, China
| | - Jing Pu
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Heng Zhao
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Ying Zhang
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Lichun Wang
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Ya Jiang
- Mile Center for Disease Control and Prevention, Mile, China
| | - Jin Lei
- Gejiu Center for Disease Control and Prevention, Gejiu, China
| | - Yan Zheng
- Yunnan Center for Disease Control and Prevention, Kunming, China
| | - Yun Liao
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Runxiang Long
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Li Yu
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Pingfang Cui
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Huijuan Yang
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Yuehui Zhang
- Gejiu Center for Disease Control and Prevention, Gejiu, China
| | - Jingyu Li
- Yunnan Center for Disease Control and Prevention, Kunming, China
| | - Weiwu Chen
- Mile Center for Disease Control and Prevention, Mile, China
| | - Zhanlong He
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Kaili Ma
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Chao Hong
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Dandan Li
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Guorun Jiang
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Donglan Liu
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Xingli Xu
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Shengtao Fan
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Chen Cheng
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Hongling Zhao
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Jianbo Yang
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Yan Li
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Yanxiang Zou
- Yunnan Center for Disease Control and Prevention, Kunming, China
| | - Youshuai Zhu
- Mile Center for Disease Control and Prevention, Mile, China
| | - Yaling Zhou
- Gejiu Center for Disease Control and Prevention, Gejiu, China
| | - Yingqiu Guo
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Ting Yang
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Hongbo Chen
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Zhongping Xie
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| | - Changgui Li
- National Institute of Food and Drug Control, Beijing, China
| | - Qihan Li
- Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, China
| |
Collapse
|
48
|
Davies Forsman L, Niward K, Kuhlin J, Zheng X, Zheng R, Ke R, Hong C, Werngren J, Paues J, Simonsson US, Eliasson E, Hoffner S, Xu B, Alffenaar JW, Schön T, Hu Y, Bruchfeld J. Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China. Eur Respir J 2020; 57:13993003.03463-2020. [DOI: 10.1183/13993003.03463-2020] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Accepted: 10/20/2020] [Indexed: 12/31/2022]
|
49
|
Yu S, Lv N, Hong C, Liu Z, Zhang Y. Rh-Catalyzed Annulation of Benzoic Acids, Formaldehyde, and Malonates via ortho-Hydroarylation to Indanones. Org Lett 2020; 22:8354-8358. [PMID: 33157567 DOI: 10.1021/acs.orglett.0c02986] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
A three-component reaction from readily available low-cost materials of benzoic acids, formaldehyde, and malonates for the preparation of indanones by rhodium catalysis is reported. The annulation is initiated by an ortho-hydroarylation of benzoic acids, and a Lewis acid is not required. The solvent has a significant influence to the reaction, and 2-substituted or nonsubstituted indanones are obtained by the change of solvent.
Collapse
Affiliation(s)
- Shuling Yu
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Ningning Lv
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Chao Hong
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Zhanxiang Liu
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Yuhong Zhang
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China.,State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, China
| |
Collapse
|
50
|
Horowitz M, Esakov E, Hong C, Michener C, Rose P, Hwang T, DeBernardo R, Reizes O. Transcriptomic analysis of hyperthermic intraperitoneal chemotherapy (HIPEC) in a cellular model of ovarian cancer. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|